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Chapter I

Introduction

1.1 Cytokine signal transduction and the Jak/Stat pathway
The proliferation, differentiation, growth and apoptosis of normal and malignant cells
are regulated by many different cytokines and growth factors (106). The majority of
cytokines transmit their signals through the Jak/Stat pathway (64, 110). Upon binding of
cytokines to their receptors, Jaks are activated and subsequently phosphorylate tyrosines
in the ligand-enaged receptors, which provides docking sites for signal transducer and
activators of transcription (Stats) through their SH2 domain (20). Recruited Stats are
tyrosine phosphorylated by activated Jaks (98, 109)(96, 108). Activated Stats dimerize
and translocate to the nucleus, and bind to either interferon stimulated response
elements (ISREs) or gamma interferon activated sequences (GAS) in the promoters of
cytokine-stimulated early response genes (23, 90)
1.1.1 Janus tyrosine kinases (Jaks)
Jaks are a family of cytoplasmic receptor associated protein tyrosine kinases required
for cytokine signaling. The members of Jak family were originally named Jaks,
reflecting the term “ just another kinase’(21). They were also named as Janus family of
kinases, from the name of the Roman god Janus, a two faced god of doorways (52). In
mammals, the Jak family consists of four members: Jak1, Jak2, Jak3 and Tyk2. They
range in size from 120 to 135 kDa. These kinases are ubiquitously expressed in a variety
of different cell types, with the exception of Jak3, which is only expressed by myeloid
and lymphoid cells (58, 63, 78, 97, 107, 119, 123).
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Fig.1.1 Jak/Stat pathway (Modified from: Ke Shuai and Bin Liu. 2003.
REGULATION OF JAK-STAT SIGNALING IN THE IMMUNE SYSTEM. Nature
Reviews, 3: 900-911)
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Based on the sequence homologies, the structure of Jaks can be divided into seven Jak
homology (JH) domains (Fig.1.2). JH1 is a kinase domain and JH2 is psuedokinase
domain. Although the JH2 domain in Jaks lacks catalytic activity, it does possess an
important regulatory function in modulating the kinase activity of Jaks (65, 69, 103).
JH3 and JH4 comprise an SH-2-like domain without a critical arginine residue required
for mediating interactions with phospho-tyrosine residues. JH6-JH7 forms a FERM
[Four-point-one (4.1), Ezrin, Radixin, Moesin] domain which has been implicated in
targeting the kinase to the cell-surface. It also regulates the catalytic activity of the
kinase domain (48, 50, 96, 110) .
The essential function of the Jaks in cytokine and interferon signaling has been
documented using various Jak-deficient cell lines and mice. The phenotype of various
Jak-deficient mice is listed in Table.1.1. Jak1-/- mice have a perinatal lethal phenotype,
probably related to the neurological defects that prevent them from suckling (101, 109).
These mice also have defective lymphoid development and function as a result of
defective signaling by cytokines through Jak1. Jak2-/- mice are lethal at embryonic day
12.5 as a result of a failure in erythropoiesis (81, 87). Interestingly, Jak3 deficiency was
first identified in humans with autosomal recessive severe combined immunodeficiency
(SCID) (71, 102, 117). Jak3-/- mice are not lethal but show severe impairment in the
development of T, B and NK cell populations and display a SCID phenotype (83, 88).
Tyk2-/- mice are described in section 1.2.1.
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Fig. 1.1 Domain structure of JAK. JH: JAK homology. Adapted from Silvernnoinen P.
S. a. O. et al, 2003 (109))
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Table 1.1 Phenotype of JAK knockout mice (Adapted from O'Shea et al., 2002 (84))
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1.1.2 Stats: structure and functional domains
In mammals, seven Stat members have been identified: Stat1, Stat2, Stat3, Stat4, Stat5a,
Stat5b and Stat6 ranging in size from 700-900 amino acids resulting in proteins of 80 –
120 kDa (22, 43, 139). Alternative splicing of primary transcripts results in the
generation of a β isoform of many Stats 1,3,4, 5, namely Stat1β, Stat3β, Stat4β and
Stat5β(12, 100). The β isoforms lack part of the C-terminal transactivation domain and
a conserved serine phosphorylation site.
Based on sequence homology, the structures of Stat proteins can be divided into several
domains: an N-terminal regulatory domain (NTD), a coiled-coil domain (CC), a DNAbinding domain (DBD), a SH2 domain (SH2), a linker domain (LD) and a C-terminal
transactivation domain (TAD) (43, 64, 113). The general domain structure of Stats is
depicted in Fig.1.2.
The N-terminal regulatory domain, comprising the first 120 to 150 amino acids, is
highly conserved and involved in: (i) the interaction of Stats with cytokine receptors, (ii)
dimer-dimer interactions to form tetramers or oligomers of Stats, (iii) the interaction
with a number of co-activators, such as CBP/p300, c-Jun, and Nmi, (iv) the regulation
of dephosphorylation of Tyr701 in Stat1, and (v) nuclear translocation.
The coiled-coil (CC) domain is located between residues 136 and 315 and consists of
four α-helices. It is important for mediating protein-protein interactions of Stats with
other proteins of the transcription machinery (6, 15). Stat2’s CC domain interacts with
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Fig. 1.3: Domain structures of STAT proteins (Adapted from Bowman et al., 2000
(9))
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N-myc interacting protein (Nmi) (140), while the CC domain of Stat3 interacts with cJun (138).
The DNA binding domain (approx. aa 320-480) mediates direct contact of Stat with the
Stat consensus core DNA sequence.

This domain determines the DNA binding

specificity (32, 99), and is also important for nuclear translocation of the Stat dimers.
The linker domain (amino acids 480 to 575) is highly conserved, but its role in Stat’s
function is not clear. One study reported that the linker domain of Stat1 mediates
gamma interferon-driven transcription. Another group reported that the linker domain of
Stat3 can serve as a site of interaction with Grim19, a component of the mitochondrial
electron transport chain (67).
The SH2 (src homology domain 2) domain is located between amino acid 550 and 670
and is required for the recruitment of Stats to phosphorylated receptors and for the
reciprocal SH2-phosphotyrosine interactions between monomeric Stats to form dimers
(41, 44).
The transcriptional activation domain (TAD) at the C-terminal region between
approximately amino acid 700 and 851, is the least conserved domain in Stats. It plays
an important role in enhancing the transcription efficiency of Stat proteins by promoting
the association of Stats with other activators or co-activators of the transcriptional
machinery, including CBP/p300, MCM5, and BRAC1 (7, 38, 73, 86, 89, 92, 136, 137).
A conserved serine in Stat1 (S727), 3 (S727), 4(S722) and 5 (S726/731) can be
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phosphorylated

and

regulates

transcription.

Several

studies

report

reduced

transcriptional activity when this serine is replaced by alanine (128).
Stat3 is described in great details in section 1.3.
1.2 Tyk2
1.2.1 Biological functions of Tyk2
Tyk2 was the first Jak to be implicated in IFNα/β signaling. Subsequent studies indicate
that Tyk2 is essential for IL-12 signaling but not for cytokines that use gp130. Tyk2
plays a critical role in host defense. Tyk2-deficient mice are viable and fertile, but
exhibit a number of defects when challenged with pathogens. Tyk2-/- mice are resistant
to LPS-induced toxic shock due to a defect in LPS-induced nitric oxide (NO)
production in macrophages (57). Loss of Tyk2 results in impaired type I IFN and IL-12
signaling (56, 108).

Tyk2-/- mice display enhanced susceptibility to lymphocytic

choriomeningtis virus (LCMV) infection due to the defect of Tyk2-/- T cell responses.
The defect of Tyk2-/- NK cell activity has been reported to be a major mechanism by
which Tyk2-/- mice develop Abelson-induced B lymphoid leukemia/lymphoma as well
as TEL-JAK2–induced T lymphoid leukemia with a higher incidence and shortened
latency compared with WT controls (111). IFNγ production by IL-12 was blunted in
Tyk2-/- DC (1, 118), resulting in a Th2 cytokine phenotype. Decreased Th1 cytokine
production in Tyk2-/- mice confers an enhanced Th2 cell-mediated allergic response. A
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single Tyk2-/- individual has been reported with hyper-IgE syndrome (74). This patient
displayed increased susceptibility to various microorganisms including viruses, fungi
and mycobacteria. The patient’s T cells displayed impaired Th1 and accelerated Th2
differentiation, almost complete defects in T cells in both IL-12 and IFNα/β signaling
and severe defects in IL-6 and IL-10 signaling.
1.2.2 Tyk2 and cancer
Aberrant activation of Jak tyrosine kinases has also been implicated in various human
malignancies (124). Jaks may induce transformation upon constitutive activation. For
example, Jak1 has been shown to be involved in malignant transformation by the v-abl
as well as by the v-src oncogene (75), and an abnormal fusion of Tel to Jak2 results in
constitutive activation of Jak2, which induces leukemia in mice and humans (61, 91).
Constitutive activation of Jak1 and Jak2 has been shown in mouse T cell lymphomas.
The Jak kinase inhibitor—tyrphostin AG490 has been shown to suppress the growth of
human prostate cancer cells (82). Exposure to tyrphostin AG490 increases metastatic
breast cancer cell response to the proapoptotic effects of doxorubicin (36).
Phosphorylated Jak1 expression was elevated in ERα-negative breast cancer cell lines
but was low in ERα-positive breast cancer cell lines (131). There is very limited
information concerning the role of Tyk2 in the pathogenesis of tumor development.
Expression of Tyk2 and its signaling enhances invasiveness of prostate cancer cells in
vitro without affecting the cellular growth rate (51). In contrast, Tyk2-/- mice develop
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Abelson-induced B leukemia as well as Tel-Jak2–induced T leukemia with a higher
incidence and shortened latency compared with WT mice (111).
1.3 Stat3
1.3.1 Biology of Stat3
Stat3 was initially identified as the acute-phase response factor (APRF) activated by IL6 (125). Besides IL-6, Stat3 can be activated by other members of IL-6 family, many
cytokines, growth factors as well as oncogenes. In addition to phosphorylation by the
Jak kinases, Stat3, can be tyrosine phosphorylated in cells that express constitutively
activated members of the Src family of tyrosine kinases (35, 68, 80, 121, 132, 133).
Stat3 has two splice isoforms: Stat3α and Stat3β. Compared to Stat3α, Stat3β has 7
amino acids that are not present in Stat3α, but lacks the 55-C terminal amino acids of
Stat3α. This splice product lacks the Ser 727 phosphorylation site. Stat3β functions as
a dominant negative with regard to Stat3α transcription, but its expression can also
activate a Stat3-responsive promoters in the absence of added cytokines (105). Although
Stat3β deficient mice are viable and fertile, they exhibit a reduced recovery from LPSinduced endotoxic shock and enhanced activation of pro-inflammatory cytokines (72,
130). Stat3α-null mice are perinatally lethal and exhibit breathing difficulties and
cyanosis (72). These findings suggest that these isoforms of Stat3 have distinct
functions in mediating immune responses and mammalian development.
Stat3α/β null mice are embryonic lethal (116). Cre-lox technology allows abrogation of
Stat3 expression in any desired tissue (Table 1.3). Studies with Stat3 deficiency in
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different tissues have provided strong evidence that Stat3 expression plays a central role
in the control of cell growth, and host responses to inflammation and cellular stress.
Wound-healing processes are severely impaired in mice with Stat3 deficient epidermal
and follicular keratinocytes (104). These mice spontaneously develop ulcers with age,
and the migration of Stat3-deficient keratinocytes is impaired in response to growth
factor stimulation in vitro.
Stat3 deficiency in hepatocytes severely impairs the IL-6 induced acute-phase response
in the liver during inflammation.
Mice with Stat3 deficiency in B cells display defects in T-dependent differentiation of
IgG B cells as well as increased sensitivity of peritoneal B-1 cells to radiation induced
apoptosis (29, 85). Mice with Stat3 deficiency in T cells have decreased IL-6 –
dependent T cell proliferation and survival (115).
Deletion of Stat3 in granulocytes leads to excessive proliferation in response to G-CSF
(62). Mice with Stat3 deficiency in myeloid cells display increased sensitivity to
endotoxin/LPS mediated toxic shock and develop inflammatory bowel disease, due to
abolished inhibitory effects of IL-10 on inflammatory cytokine production (114, 127).
Similar findings are seen when Stat3 is deficient in cardiomyocytes, endothelial cells or
hepatocytes (2, 53, 55). Both LPS and ischemia activate Stat3. These mice are also
hypersensitive to challenge with LPS and show enhanced inflammation in multiple
organs.
The expression of Stat3 in the heart is associated with cardiac survival (45). Mice with
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Table 1.2 Phenotypes of tissue-specific conditional Stat3-null mice. (Adapted from
Levy and Darnell, 2002 (64)).
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Stat3 deficiency in cardiomyocytes develop increased cardiac inflammation with
fibrosis, dilated cardiomyopathy and early death due to congestive heart failure (46, 53).
Female mice with Stat3 deficiency in cardiomyocytes develop post partum
cardiomyopathy which is also seen in humans with reduced Stat3 expression in the
myocardium. Stat3-null hearts have been shown to have elevated levels of ROS (47).
In addition, the pharmacological suppressor of ROS tetrakis (4-benzoic acid) porphyrin
(MnTBAP), a substance with catalytic activities similar to MnSOD, attenuated ROS
production in the heart and prevented the onset of post partum cardiomyopathy when
given to mice that do not express Stat3 in the heart (47).
Taken together, these studies support the hypothesis that expression of Stat3 in the heart
protects it from a variety of stresses induced by ischemia, endotoxin and drugs such as
doxorubicin. These stresses all induce the formation of ROS. One major source of ROS
is decreased activity of complex I of the electron transport chain in mitochondria.
1.3.2 Relationship between Grim19 and Stat3
Gene associated with retinoid-interferon-induced mortality19 (GRIM-19) is essential for
breast cancer cell death induced by interferon β (IFN β) and retinoic acid (RA) (4). Both
IFN β and RA can increase the expression of Grim-19. The interaction of GRIM-19
and Stat3 was first observed in a yeast two-hybrid screen (4, 67, 135). GRIM-19 has
also been implicated as a mediator of activation of NF-kB by bacterial muramyl peptide
which binds to NOD2 (5) ). Grim-19 null mice are embryonic lethal.
Grim-19 was purified as a subunit of complex I of the mitochondrial electron transport
chain (ETC) (13, 28, 77). Grim-19 is essential for assembly of complex I since Grim-19
14

-/-

ES cells fail to form complex I of the ETC (49). In addition, the loss of Grim-19 also

influences the assembly of complex II of the ETC (49). Two recent publications
indicate that a small fraction of Stat3 is located within the mitochondria of cells. The
expression of mitochondrial-localized Stat3 (mitoStat3) modulates the activity of
complexes I, II, and V of the electron transport chain in a variety of cells as well as
primary cardiac tissue (126). Furthermore, the expression of mitoStat3 restores the
ability of Stat3-/- MEFs to be transformed by Ras (39).
1.3.3 Stat3 and Cancer.

A number of studies demonstrate that overexpression of Stat3 in cells promotes cell
growth and transformation (30). Many tumors display increased levels of tyrosine
phosphorylated Stat3. Approximately 75% of primary human breast cancers and
prostate cancers show elevated levels of tyrosine phosphorylated Stat3 in nuclei (30).
Constitutively activated Stat3 has been seen in a wide variety of human tumors,
including head and neck, lung, prostate and breast cancers, CNS tumors, multiple
myelomas and lymphomas (30). Inhibition of constitutive Stat3 activity blocks the
proliferation and survival of breast cancer cells in vitro (11) and in vivo (66). Decreased

patient survival is strongly correlated with Stat3 activation in leukemia and other tumors.
Stat3 is essential for mammary development. When lactation terminates, leukemia
inhibitory factor (LIF) activates Stat3. Activated Stat3 then results in involution of the
mammary gland (14, 16).
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As mentioned above, Stat3 is frequently constitutively active in breast cancer. Increased
levels of Stat3 phosphorylation are associated with metastasis to regional lymph nodes
and the expression of the progesterone receptor (24, 34, 121, 122). In addition, clinical
studies demonstrate that increased levels of Stat3 phosphorylation in patients with stage
II breast cancer correlated with an incomplete response to neo-adjuvant chemotherapy
(42).
Although constitutive tyrosine phosphorylation of Stat3 has been implicated in the
pathogenesis of many cancers, there is accumulating evidence suggesting that serine
727 phosphorylation of Stat3 can contribute to or be sufficient for growth and/or
transformation of some malignancies. Overexpressed Stat3 S727A is reported to exert a
dominant–negative effect on v-Src-mediated transformation (10). A phosphomimetic of
serine 727 of Stat3 accelerated the tumorigenesis of human prostate cancer cells in the
absence of the protein being tyrosine phosphorylated (94). Patients with chronic
lymphocytic leukemia (CLL) express constitutive serine phosphorylation of Stat3 in the
absence of tyrosine phosphorylation of the protein (8). Serine phosphorylation of Stat3
was observed in all patients with CLL and was absent in normal peripheral blood B
lymphocytes. In addition, expression of Stat3 Y705F/S727E promotes prostate
tumorigenesis (94). Furthermore, 65% of primary human prostate cancers displayed
constitutive serine phosphorylation of Stat3 (94). However, the role of Stat3 serine 727
in tumor growth and invasion of these tumor cells is unclear.
1.4. Immune system and antitumor immune responses
The immune system defends the host against a wide range of pathogens as well as
16

aganinst tumor cell growth. Serving as the first line of defense, innate immunity is
essential for the control of common bacterial infections. However, it is not specific to a
particular pathogen. Phagocytic cells, such as macrophages, play an important role in
many aspects of innate immunity. In contrast, adaptive immunity displays specificity as
well as memory.

In the adaptive immune response, lymphocytes, which express

diverse antigen-specific receptors, enable the immune system to recognize specific
foreign antigens. Besides eliminating pathogens, the adaptive immune response can
generate increased numbers of memory lymphocytes, which allow a more rapid and
effective reaction upon reinfection.
1.4.1. Innate immunity
Phagocytes

The phagocytic cells of the immune system include macrophages,

neutrophils, and dendritic cells (DCs). Macrophages present in peripheral blood are
called as monocytes. Monocytes are able to move across capillary vessels and enter
into tissues. Macrophages are the most efficient phagocytes. The binding of bacterial
pathogens to their receptors on macrophages triggers them to engulf and destroy the
bacteria through the generation of a “respiratory burst”, causing the release of reactive
oxygen species (ROS). Pathogens also stimulate macrophages to produce chemokines
which recruit other cells to the site of infection. Neutrophils secret toxic substances that
kill or inhibit growth of bacteria and fungi. Basophils release histamine, important in
defense against parasites when activated by pathogens. Upon activation, eosinophils
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secrete a range of highly toxic proteins and free radicals that are highly effective in
killing bacteria and parasites, but are also responsible for tissue damage occurring
during allergic reactions. DCs are mainly present in skin, and in the inner mucosal
lining of the nose, lungs, stomach and intestines. They are the major antigen presenting
cells.
Natural killer (NK) cells

NK cells are the first defense against tumor cells. They

recognize and eliminate tumor cells by two major strategies: (i) many tumor cells
downregulate class I major compatibility complex (MHC) molecules, thus releasing the
NK cell from the inhibition provided by MHC I –specific inhibitory receptors. NK cells
can access tumor cells which down-regulate MHC I molecules, and (ii) NK cells
recognize structures that are specifically up-regulate on tumor cells, e.g., Rae1, H60 and
MIC proteins. Activated NK cells secret immune modulatory cytokines that directly aid
in the clearance of pathogens and also indirectly augment a developing adaptive
immune response. For example, NK cell-derived interferon-γ (IFN-γ) can directly affect
the growth and immune recognition of virally infected cells as well as promote the
differentiation of naïve CD4+ T cells into Th1-type helper effector cells. Thus, NK cells
are able to promote an innate as well as a specific immune response to intracellular
pathogens and malignant cells via the secretion of specific cytokines.
γδ T cells

γδ T cells may function as a part of the innate immune system since a

restricted T-cell receptors serve as a pattern recognition receptor. In addition, they are
capable of rearranging T cell receptor (TCR) genes to produce a diversity and develop a
18

memory phenotype. Thus, γδ T cells may also be considered as a component of
adaptive immunity.
1.4.2 Adaptive immunity
T helper (T h, CD4+ T) cells CD4+ T helper cells are divided into two types: Th1 and
Th2. The Th1 response is characterized by the production of interferon (IFN)-γ, which i)
activates macrophages to kill bacteria, and ii) induces B cells to make opsonizing
antibodies and leads to cell-mediated immunity; iii) help to activate CD8+ T cells; iv)
induce apoptosis of tumor cells. The Th2 response is characterized by the release of
interleukin-4 (IL-4), which results in the activation of B cells to make neutralizing
antibodies, leading to humoral immunity. Generally, Th1 responses are more effective
against intracellular pathogens (viruses and bacteria that are inside host cells), while
Th2 responses are more effective against extracellular bacteria, parasites and toxins.
CD4+ T cells have no cytotoxic or phagocytic activity and can not kill infected cells or
+

clear pathogens as CD8 T cells do, but they can activate other immune cells to perform
these tasks.
Cytotoxic T cells (CTL, CD8+ T cells ) Cytotoxic T cells (CTL, CD8+ T cells) induce
the death of cells that are infected with viruses (and other pathogens), or are damaged or
dysfunctional. Once activated, the CD8+ T cells undergo colonal expansion, become
functional and divide rapidly into effector cells. Activated CD8+ T cells will travel
throughout the body in search of cells bearing that unique MHC class I peptide.
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CD8+ T cells are key for the host to control intracellular infections and cancer. They act
as cytolytic T lymphocytes (CTLs) that not only eliminate in a cytotoxic manner the
infected/tumor cells but also carry out regulatory functions, being capable of either
suppressing or supporting immune responses. When exposed to infected or
dysfunctional cells, effector CD8+ T cells release perforin and granulysin, which form
pores in the target cell plasma membrane, allowing ions and water to flow into the
infected cell and causing it to lyse. CD8+ T cells also release granzyme, a serine
protease that enters cells via pores to induce apoptosis.
B cells

B cells are antibody-producing cells. Antibodies identify and neutralize

foreign objects. Upon activation, B cells produce antibodies, which recognize a unique
antigen and neutralizes specific pathogens. These antibodies bind to antigens, making
them easier targets for phagocytes, and trigger the complement cascade.
Roles in tumor: MHC, not
1.4.3 Antitumor immune responses
The battle between cancer progression and the immune system of the host can be
divided into three phases (Fig.1.3) : elimination, equilibrium and escape (37).
Elimination

phase The immune system plays a major role in the host defense against

tumor cell growth (Fig.1.5) (37). Once tumors grow to a certain size, they become
invasive. Invasive growth causes disruptions to the surrounding tissue that induce
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inflammatory signals leading to recruitment of NK cells, γδ T cells, marcrophages and
dendritic cells to the tumor site, thus initiating an immune response. These cells are
then stimulated to produce IFNγ. IFNγ plays important roles in:

(i) inducing

chemokines, including the angiostatic chemokines that block neovascularization in the
tumor; (ii) inducing apoptosis of tumor cells and (iii) inducing cytocidal activity of
macrophages and NK cells entering the tumor. These events result in some tumor cell
death by both immunologic and nonimmunologic mechanisms. Dead tumor cells or
tumor cell debris are ingested by dendritic cells and migrate to the tumor draining
lymph nodes. Tumor growth is kept in check by the cytocidal activities of NK cells and
activated macrophages, while CD4+ and CD8+ T cells that are specific for tumor
antigens develop in the draining lymph node. CD4+ and CD8+ T cells then infiltrate into
the tumor along a chemokine gradient where they recognize and destroy tumor cells
expressing distinctive tumor antigens. The elimination phase can be complete, when all
tumor cells are cleared, or incomplete, when only a portion of tumor cells are eliminated.
Partial tumor elimination leads to an equilibrium phase.
Equilibrium phase The pressure exerted by the immune system during this phase is
sufficient to control tumor progression, but eventually, if the immune response still fails
to completely eliminate the tumor, the process results in the selection and/or promotion
of tumor cell variants with increasing capacities to survive immune attack, leading to
the escape phase. Here is evidence of the existence of an equilibrium phase. A report
described the occurrence of melanoma 1–2 year post-kidney transplant in allograft
21

Figure.1.4 Three phases of cancer cells against hosts. (a) Elimination. (b)
Equilibrium. (c) Escape. In a and b, developing tumor cells (blue), tumor cell variants
(red) and underlying stroma and nontransformed cells (gray) are shown; in c, additional
tumor variants (orange). The small orange circles represent cytokines and the white
flashes represent cytotoxic activity of lymphocytes against tumor cells. (Adapted from:
Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from
immunosurveillance to tumor escape (37)).
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Figure 1.5 Model of Innate Recognition and Initiation of the Adaptive Antitumor
Immune Response (a) The initiation of the immune response in which lymphocytes
(NKT, NK and γδT cells) are recruited to the tumor site, recognize transformed cells,
and are stimulated to produce IFN-γ. (b) IFN-γ starts a cascade of innate immune
reactions. (c) Tumor growth is kept in check by the cytocidal activities of NK cells and
activated macrophages, while CD4+ and CD8+ T cells that are specific for tumor
antigens develop in the draining lymph node. (d) Tumor-specific CD4+ and CD8+ T
cells home to the tumor along a chemokine gradient where they recognize and destroy
tumor cells expressing distinctive tumor antigens. Tumor cells (blue); nontransformed
cells (gray); dead tumor cells (white to gray gradient circles surrounded by a dashed
black line); lymphocytes, dendritic cells (DC) and macrophages (Mac) are shown in
different colors. (Adapted from: Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD.
Cancer

immunoediting:

from

immunosurveillance
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to

tumor

escape

(37)).

recipients who received kidneys from a donor who had primary melanoma and treated
and was considered tumor free at the time of kidney donation (121). Latent melanoma
starts to grow in the recipient who was taken immunosuppressive drug.
Escape phase Tumor cells emerge that either display reduced immunogenicities or
engage a large number of possible immunosuppressive mechanisms to attenuate
antitumor immune responses leading to the appearance of progressively growing tumors.
For example, MDSCs promote tumor development.
MDSCs Myeloid derived suppressor cells (MDSCs) are a heterogeneous population of
undifferentiated cells that express markers of monocytes (CD11b) and neutrophils (Gr1).
They accumulate in the bone marrow, blood, spleen, lymph nodes, and at the tumor site
in tumor-bearing hosts as tumor burdens increase (79). They suppress T cell
proliferation, increase T cell death by apoptosis, foster T cell tolerance, and change the
profile of cytokines secreted by activated T cells (79). They also inhibit T cell function
by inducing the development of CD4+CD25+FoxP3+ T regulatory cells which suppress
immune responses (79). Importantly, increased levels of circulating MDSCs have
recently been correlated with disease stage and extensive metastatic tumor burden in
patients with breast cancer (79).
MDSCs exert their immunosuppressive effects primarily through the production of
arginase-I, nitric oxide synthase, and reactive oxygen species as well as by cell contact
dependent cross talk with macrophages that results in decreased IL-12 production by
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macrophages and increased IL-10 production by MDSCs (79). There may also be direct
contact dependent inhibition of T cell proliferation (79).
1.4.4 The effects of immune cells on tumor development
Immune components play an important role in tumor development. However, not all
immune components play roles in all models of cancer. The effect of T cells and NK
cells on tumor development depends on the origin of tumors. For example, CD4+ T
cells protect mice from human papilloma virus (HPV)-induced cervical carcinoma,
whereas both CD4+ T cells and B cells enhance? tumor incidence in HPV-induced skin
carcinogenesis in mice (18, 19, 54). In a two-stage chemical carcinogenesis protocol to
induce skin cancer, αβ T cells promoted cancer at high doses of carcinogen, whereas γδ
T cells inhibited tumor formation at low doses of carcinogens (70). Finally, whereas
CD8+ T cells have been shown to perform a host-protective role in many models of
murine and human cancer, this tumoricidal T cell population either plays no role or has
a small tumor-promoting role in the HPV-induced skin cancer models (19, 25, 27, 60).
1.5 Breast cancer and 4T1 mouse mammary carcinoma model
Breast cancer is the most common cancer among women and is the second leading
primary cause of cancer deaths in women in United States. Currently, one in nine
American women will develop breast cancer. The rate of breast cancer incidence has
increased 2-3% per year over the past decade in both premenopausal and
postmenopausal women. Every year approximately 200,000 women are diagnosed with
breast cancer, of which 40,000 will die from the disease.
25

The risk factors known to increase the chance of developing breast cancer include age, a
family history of breast cancer, an early age of a first menstrual period, a late age of
menopause, a late age at the time of birth of her first full-term baby, and obesity in
postmenopausal women. These factors alter expression and/or activity of genes that
control cellular growth, proliferation and survival. A major obstacle in the cure for
breast cancer is to elucidate the mechanisms by which these genes regulate and control
cellular proliferation.
The 4T1 mouse mammary carcinoma is a BalB/c-derived tumor that spontaneously
metastasizes from the primary tumor site to multiple distant sites including blood, brain,
lung, liver, bone and lymph nodes. The 4T1 tumor has four important charactertics that
make it a suitable experimental animal model for human breast cancer (93). First, 4T1
tumor cells are easily transplanted into the mammary gland so that the primary tumor
grows in the anatomically correct site. Second, similar to human breast cancer, 4T1
metastatic disease develops spontaneously from the primary tumor. In addition, the
progressive spread of 4T1 metastases to the draining lymph nodes and other organs is
very similar to that of human mammary cancer. Third, metastatic foci remain intact
after surgical removal of the primary tumor. This makes it possible to study metastatic
disease in an animal comparable to the clinical situation where the primary tumor is
surgically removed. Fourth, 4T1 cells are resistant to 6-thioguanine. This property
enables precise quantitation of metastatic cells by clonogenic assay.
1.6 Reactive oxygen species (ROS) and their effects on tumor growth
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Reactive Oxygen Species (ROS) include: hydroxyl (OH•), superoxide (O2•¯), nitric
oxide (NO•), thyl (RS•), peroxyl (RO2•), lipid peroxyl (LOO•), hypochloric acid
(HOCl), hydrogen peroxide (H2O2), singlet oxygen (¯1O2), ozone (O3), lipid peroxide
(LOOH). Reactive Nitrogen Species (RNS) are radical nitrogen-based molecules that
can act to facilitate nitrosylation reactions. Common RNS in cells include: dinitrogen
trioxide (N2O3), mitrous oxide (NO•), nitroxyl anion (NO¯), nitryl chloride (NO2Cl),
nitrosyl cation (NO+), nitrogen dioxide (NO2•), nitrous acid (HNO2) and peroxynitrite
(OONO¯), peroxynitrous acid (ONOOH).
The major intracellular superoxide is derived from complex I and III of the electron
transport chain (ETC) in mitochondria of nonphagocytic cells (Fig.1.5) (76).
Superoxide may react with NO, yielding the highly reactive oxidizing peroxynitrite,
which can react with protein tyrosine residues to form 3-nitro-L-tyrosine. In addition,
superoxide is also converted into hydrogen peroxide by manganese superoxide
dismutase (MnSOD). H2O2 induces celluar apoptosis.
Cells have an antioxidant defense system (ADS) to prevent oxidative damage and
control its spread. There are also enzymes (i.e., superoxide dismutase (SOD), catalase,
glutathione peroxidase) to repair oxidative damage. Essential antioxidants are either
endogenous (internally synthesized) or exogenous (consumed).
Oxidative stress occurs when the generation of ROS exceeds the ability of the ADS to
neutralize and eliminate them. Excess ROS can damage a cell’s lipids, protein or
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Fig.1.6 Production of O2•- by complex I (Adapted from Michael P. Murrhy, 2009 (76))
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DNA, inhibiting normal function. Oxidative stress has been implicated in human
diseases as well as in the aging process. Nitrosative stress occurs when the generation
of RNS in cells exceeds the cells’s ability to neutralize and eliminate RNS.
Nitrosative stress may lead to nitrosylation reactions that can alter protein structure,
thus inhibiting normal function.
Elevated ROS has been found in many types of cancer cells, and has been shown to
carcinogenesis (3, 26, 59, 95, 112, 129). ROS is also implicated in tumor metastasis
(95, 112). The effects of oxidative stress on tumor cells include: 1) increased mutation
rate of DNA and accelerated tumor progression; 2) sustained oxidative stress at
sublethal levels may confer resistance to apoptosis induced by oxidative stress and
oxygen radical induced DNA damage; 3) increased risk of metastasis; 4) activation of
growth-promoting mitogen activated protein kinase (MAPK) signaling pathways; 5)
increased blood supply to tumor cells; 6) severe oxidative stress leads to apoptosis.
ROS/RNS also modify protein structure, for example, interactions with metal-thiol
clusters, protein cysteine oxidation, protein tyrosine nitration, S-thiolation and Snitrosylation.

Tyrosine-nitrated proteins have been viewed as end products that

induce downstream events destined for protein degradation. As a result, protein
nitration is a marker for the extent of ROS production and therefore cellular stress
states.
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Chapter II Tyk2 deficiency promotes primary tumor growth
and metastasis
2.1 Abstract
Aberrant activation of the Jak/Stat pathway has been associated with tumor formation.
Constitutive activation of Jak2 kinase induces leukemia in mice. Constitutive activation
of Jak1 and Jak2 has been shown to occur in mouse T cell lymphomas. We show here
that Tyk2-deficient mice show enhanced primary tumor growth and metastasis of breast
cancer cells. Tumor-bearing Tyk2–/– mice also have higher levels of myeloid-derived
suppressor cells than tumor-bearing wild type mice. We also show that Tyk2-/- mice
produce less IFNγ than wild type mice. Depleting CD4+ T cells does not impact 4T1
tumor growth. Neither NK cells nor CD8+ T cells contribute to increased tumor growth
in Tyk2-/- mice. Tyk2-/- MDSCs have a slight increase in suppression of T cell
proliferation. Taken together, our results suggest that Tyk2 deficiency in the host
promotes breast cancer development.
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2.2 Introduction
The Jak/Stat pathway regulates cell proliferation, differentiation, growth and apoptosis
of normal and malignant cells (12, 17, 27). In mammals, the Jak family has four
members: Jak1, Jak2, Jak3 and Tyk2 (17, 35). When ligands bind to their receptors,
Jaks are activated, and they in turn phosphorylate the intracellular domain of cytokine
receptors. Phosphorylated tyrosine residues in the receptors provide docking sites for
Stats, and Stats recruited to the receptor are phosphorylated by the Jaks (15, 8, 17).
Tyrosine phosphorylated Stats dimerize and translocate to the nucleus, and bind to
either interferon stimulated response elements (ISREs) or gamma interferon activated
sequences (GAS).
Aberrant activation of Jak-Stat signaling had been shown o occur in many solid tumors
and leukemia (2, 3, 5, 6, 7, 9, 12). Both Stat3 and Stat5 display oncogenic properties
when expressed ectopically. Constitutive activation of Stat3 has been shown in over 20
human cancers. A constitutively active mutant of Stat3 transformed rat fibroblasts (43),
and the enforced expression of WT Stat5 in the lymphoid lineage induced T cell
leukemia in mice (24). Stat1 has been shown to be a tumor suppressor. Stat1–/– mice
have been repeatedly used to study the role of IFN-γ in tumorigenesis and tumor
surveillance (20, 32). Recent evidence indicates that Stat1 acts as a tumor suppressor by
modulating apoptosis (36). In addition, constitutive ly activated Jaks may induce
transformation. For example, Jak1 has been involved in malignant transformation by the
v-abl as well as by the v-src oncogene (7, 42) and abnormal fusion of Tel to Jak2 results
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in constitutive activation of Jak2, which induces leukemia in mice and humans (5, 25).
Constitutive activation of Jak1 and Jak2 has been shown in mouse T cell lymphomas.
Inhibition of Tyk2 expression by siRNA or blockage of Tyk2 signaling by inhibitors of
Tyk2 result in attenuation of the urokinase-type plasminogen activator-enhanced
invasiveness of prostate cancer cells in vitro without affecting the cellular growth rate
(16).

Tyk2-/- mice are reported to develop Abelson-induced B lymphoid

leukemia/lymphoma as well as Tel-Jak2–induced T lymphoid leukemia with a higher
incidence and shortened latency compared with WT mice (37). Jak1 was also shown to
be a tumor suppressor downstream of IFN-γ in a B lymphoid tumor model (38).
Studies with Tyk2-/- mice revealed the critical role of Tyk2 in host defense: Tyk2deficient mice are viable and fertile, but exhibit a number of defects when challenged
with pathogens. Tyk2-/- mice are resistant to LPS-induced toxic shock due to a defect in
LPS-induced NO production in macrophages (19, 22). Loss of Tyk2 results in impaired
type I IFN and IL-12 signaling (21, 23). Tyk2-/- mice display enhanced susceptibility to
lymphocytic choriomeningtis virus (LCMV) infection due to the defect of Tyk2-/- T cell
responses (21). The defect of Tyk2-/- NK cell activity has been reported to be a major
mechanism

by

which

Tyk2-/-

mice

develop

Abelson-induced

B

lymphoid

leukemia/lymphoma as well as TEL-JAK2–induced T lymphoid leukemia with a higher
incidence and shortened latency compared with WT controls (37). IFNγ production
induced by IL-12 was blunted in Tyk2-/- DC, resulting in a Th2 cytokine phenotype (1,
39). Decreased Th1 cytokine production in Tyk2-/- mice confers enhanced Th2 cell32

mediated allergic response. A single human has been identified who does not express
Tyk2. This individual displays more severe defects than Tyk2-/- mice (23). The patient
showed increased susceptibility to various microorganismisms including virus, fungi
and mycobacteria. The patient’s T cells display impaired Th1, and accelerated Th2
differentiation. T cell response to IL-12, α/β, IL-6 and IL-10 were also nearly absent.
Based on available evidence, it is unclear what role Tyk2 plays in tumor formation. To
explore the role of Tyk2 in the pathogenesis of breast cancer, we used the 4T1 mouse
breast cancer model which shows many features with human breast cancer. Our results
show that Tyk2–/– mice develop larger 4T1 tumors and more metastaic diseases than
wild type mice. Tumor-bearing Tyk2–/– mice also have higher levels of myeloid-derived
suppressor cells than tumor-bearing wild type mice. Tyk2-/- mice produced less IFNγ
than wild type mice. CD4+ T Depletion does not affect 4T1 tumor growth. In vivo
depletion of NK, or CD8+ T cells shows that neither Tyk2-/- NK cells alone nor CD8+ T
cells contribute to enhanced tumor growth in Tyk2-/- mice. Tyk2-/- MDSCs have a slight
increase in suppressing T cell proliferation. Taken together, our results suggest that
absence of Tyk2 promotes breast cancer growth and metastasis.
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2.3 Materials and Methods
Cells: The 6-thioguanine-resistant 4T1 mouse mammary carcinoma cell line was
purchased from the American Type Culture Collection (Rockville, MD). Cells were
grown in DMEM ( Invitrogen ) medium supplemented with 10% fetal bovine serum
( Serum Source International INC., Charlotte, NC ), plus 1.0 mM sodium pyruvate, and
100 U/mL penicillin, and 100 µg/mL streptomycin (Mediatech INC., Hemdon, VA).
Mice were subcutaneously injected in the mammary gland with 7.0 × 103 4T1 cells in
1xPBS.
Mice: BALB/c mice were purchased from Jackson Laboratory (Bar Harbor, ME). The
mice were housed in a ventilated barrier rack (Lab Products, Inc., Seaford, DE) in a
temperature-controlled facility on a 12 h light cycle. Tyk2-/- mice in a BALB/c
background were obtained from Dr. Ana M. Gamero at the National Cancer Institute
(NCI, Frederick, MD). Tyk2-/- mice were genotyped by using the following primers.
Forward primer for Tyk2 wild type mice: 5’- TGG ACA AAA TGG AGT GAG TGT
AAG-3’; reverse primer for Tyk2 wild type mice: 5’-CTG GGT CAT GGC TGG AAA
AGC CCA-3’; primers for Tyk2 null mice: 5’- GAT CGG CCA TTG AAC AAG
ATG-3’; 5’- CGC CAA GTC CTT CAG CAA TAT-3’. PCR cycling: 95 °C 4 min, 35
cycles: 95 °C 1 min, 55 °C 1 min, 72 °C 1 min, then 73 °C 10 min, 4 °C infinite. This
research was conducted under a protocol approved by Virginia Commonwealth
University, Institutional Animal Care and Use Committee.
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Reagents and antibodies: Recombinant human IL-2 (Cat. No. 200-02) was purchased
from Peprotech. 6-Thioguanine (Cat. No. A-4882), methylene blue (Cat. No. M-4159)
and Hyaluronidase (Cat. No. H3884) were purchased from Sigma, Elastase (Cat. No.
2279), Collagenase Type 4 (Cat. No. 4188) and Collagenase Type 1 (Cat. No. 4196 )
were purchased from Worthington. Antibodies are listed in Table 2.1.
Measurement of tumor growth: Tumor growth was assessed morphometrically using
calipers, and tumor volumes were calculated according to the formula V (mm3) = L
(length) × W2 (width) / 2 (4). Tumors and spleens from control and tumor-bearing mice
were weighed on a microbalance.
Metastatic tumor cell clonogenic assay: 4T1 tumor cells are 6-thioguanine-resistant.
4T1 metastatic cells can be detected and quantified by explanting organs, plating
dissociated cells in medium supplemented with 6-thioguanine, and counting the number
of 6-thioguanine-resistant colonies. This method allows for quantitative monitoring of
spontaneous metastasis development to multiple distant sites. Female mice were
challenged s.c. in the abdominal mammary gland with 7x103 4T1 tumor cells and
sacrificed at times indicated. Lungs and livers were harvested from each experimental
group. Liver samples were finely minced and digested in 5 ml of enzyme cocktail
containing 1xPBS, 0.01% BSA and 1 mg/ml hyaluronidase, and 1mg/ml collagenase
type I for 20 min at 37°C on platform rocker. Lung samples were be finely minced and
digested in enzyme cocktail containing 1xPBS, 1 mg/ml collagenase type IV at 6
units/ml for 75 min at 4°C on a rotating wheel. Brain samples were finely minced and
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Table 2.1 Anti-mouse antibodies used in this study

CD16/32
IgG Rat serum
CD3ε-PE
Asialo GM1 (rabbit)
Pan-NK-FITC (CD49b)
FITC- CD4
FITC-CD8a
CD4-PE
FITC-Gr1(Ly-6G/Ly6C)
PE/Cy5-Gr1(Ly-6G/Ly6C)
FITC rat Ly-6G
Gr1-PE/Cy5
PE-Cy5 CD4
PE-Cy5 CD8a
Ly6G-FITC
PE-CD11b
Purified hamster antimouse CD28
Purified hamster antimouse CD3e
FITC rat IgM, k
FITC rat IgG2a
PE rat IgG2a
PE Armenlan Hamster

clone
93

DX5
RM4-5

company
Biolegend
Sigma-aldrich
Biolegend
Wako pure chemical Industries, Ltd.
Biolegend
eBioscience

53-6.7
GK1.5
RB6-8C5

Biolegend
Biolegend
Biolegend

Cat.No.
101302
14131
100307
986-10001
108905
11-004281
100705
100408
108406

RB6-8C5

Biolegend

108410

1A8
RB6-8C5
H129.9
53-6.7
RB6-8C5
M1/70
37.51

Biolegend
Biolegend
Biolegend
Biolegend
BD Pharmigen
Biolegend
BD Pharmigen

101208
108410
130312
100710
551460
100705
553295

500A2

BD Pharmigen

553238

RTK2118
RTK2758
RTK2758
HTK888

Biolegend
Biolegend
Biolegend
Biolegend

400805
400505
400507
400907

145-2C11

digested for 2h at 37°C on a platform rocker with 5 ml of the same enzyme cocktail
used for lung samples. After incubation, samples were filtered through 70-µm nylon
cell-strainers and washed two or three times with 1xPBS. The resulting cells were
suspended, plated with a series of dilutions in 10-cm tissue-culture dishes in DMEM
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containing 60 µM thioguanine for clonogenic growth. Because 4T1 tumor cells are
resistant to 6-thioguanine, metastasized tumor cells formed foci after 10 to14 days, at
which time they were fixed with methanol and stained with 0.03% methylene blue.
Clonogenic metastases were calculated on a per-organ basis.
IFN-γ Production: Tyk2+/+ and Tyk2-/- female mice were inoculated with 7000 4T1
cells in mammary gland by subcutaneous injection. 96-well Plates were coated with
Coating Buffer for overnight at 4 °C. After 5 days of tumor growth, spleens were
harvested. Splenocytes (5x106) were then cocultured in the presence of IL-2 (30 U/well)
in medium (DMEM supplemented with 10% FBS, 100 U/ml penicillin, 100 µg/ml
streptomycin) in the presence or absence of irradiated 4T1 cells (4x105) (15000 rad).
After 24 h of incubation, the supernatants were collected. IFN-γ concentration in these
supernatants was determined using a Mouse IFN-γ ELISA set (BD Biosciences, San
Diego, CA) according to manufacture's protocol. Absorbance was read at 450 nm in a
microplate reader (Molecular Devices). Results are reported as the mean values of
duplicate wells. In each experiment, 4 mice per genotype were used in each group. A
total of 12 Tyk2-/- and 12 Tyk2+/+ mice were tested in three separate experiments.
Sample preparation for examination of depletion efficiency: Blood was collected
from mice via the retro-orbital sinus. Red blood cells were lysed with 1x ACK buffer
(0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM Na2EDTA). Cells were re-suspended in 1x
PBS supplemented with 2% fetal bovine serum (FBS) and 0.1% NaN3. Non-specific
binding to Fc receptors was blocked with CD16/CD32 antibody or IgG Rat serum
37

(Product number 14131,

Sigma-aldrich) for 20 min on ice. Cells were stained with

saturating amounts of surface antibodies towards various markers and incubated on ice
in the dark for 1 h. Cells then were washed twice. Flow cytometric analysis was
conducted using a BD FACS CantoTM II flow cytometer. Viable cells were collected
and analyzed using the FACScan flow cytometer and the BD FACSDiva software (BD
Biosciences).
In vivo depletion of NK cells: In vivo NK cell depletion was performed using purified
monoclonal antibodies of anti-asialo-GM1 (Wako Chemicals, Richmond, VA).
Recipient mice were injected intraperitoneally (i.p.) with 200 µg of rabbit anti-asialo
GM1 or control rabbit Ig serum before tumor inoculation. Antibody injections were
performed on day 0, 1, 7, 11, 14 and 20, where day 1 is also the day of tumor challenge.
The control group of mice was inoculated with the same amount of purified normal rat
IgG ( Product number 14131, Sigma-aldrich). NK-cell depletion was confirmed by flow
cytometric analysis of peripheral blood lymphocytes. The presence of NK cells was
examined on the following day after each antibody injection by flow analysis using antimouse FITC-Pan-NK (DX5) ( Biolegend ) and anti-mouse PE-CD3ε ( Biolegend ).
Purification of CD4+, CD8+ monoclonal antibodies: Anti-CD4 (GK1.5) and CD8
(2.43) hybridomas were injected i.p. in SCID mice and ascites fluid were collected by
the hybridoma core of Massey Cancer Center of VCU. Ascites were clarified by
centrifugation at 15000 rpm (Sorvall RC5B centrifuge, rotator SS34) for 20 min at 4 °C.
Antibody purification was performed by hydrophobic charge induction chromatography
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using MEP HyperCel sorbent (PALL Life Sciences, East Hills, NY). The MEP (4mercaptoethylpyridine) ligand is immunoglobulin-selective and can bind a broad range
of Ig isotypes and subclasses. It contains a nitrogen heterocycle and a proximal sulfur
atom which are thought to influence its specificity for Ig. Binding to Ig is achieved
through hydrophobic interactions at neutral pH, a pH at which both Ig and the pyridine
group of the ligand are uncharged. As the pH is lowered, both the ligand and the Ig
acquire positive charges, resulting in electrostatic repulsion and elution of the Ig. 10-15
ml of sorbent was poured into a 1.6 x 7.5 cm column (GE Healthcare, Piscataway, NJ)
and packed at 10 ml/min using 1x PBS. The column was equilibrated using 1x PBS
containing 250 mM ammonium sulfate. 50 ml supernatant was loaded onto the column
at a rate of 2 ml/min using a Pharmacia FPLC (GE Healthcare Bio-Sciences Corp.,
Piscataway, NJ). Elution was conducted at pH 5.3 in 50 mM MES (Fisher). Selected
fractions were separated on a NuPAGE Bis-Tris Electrophoresis System, Invitrogen).
Proteins were stained in SDS-PAGE Stain (2.5 g Commassie Brilliant Blue R-250, 100
ml glacial acetic acid, 450 ml dH2O) for 30 minutes and destained in SDS-PAGE
Destain (30% methanol, 10% acetic acid, dH2O) for ~ 2 hours. Relatively pure heavy
chain and light chain can be seen in the pH 5.5-5.0 fractions. pH 3.0 fractions
contained free light chains and other contaminants (Fig.2.1). The pH 5.3 fractions were
pooled and dialysized in 1xPBS at 4 °C. Dialysized purified monoclonal antibodies
were concentrated using an Amicon 8050 filter (Amicon, cat. No. PBGC04310), sterilefiltered and stored at -80 °C until use.
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In Vivo T-Cell Subset Depletion: In vivo T-cell depletion was performed using
purified monoclonal antibodies of anti-CD4 (GK1.5) or anti-CD8 (2.43). Mice were
depleted of CD4+ or CD8+ T cells by i.p. injection of 200 ug MAb. Antibodies were
injected on days 1, 6, 13, where day 2 is the day of tumor challenge. The presence of
CD4+ or CD8+ T cells were examined on the day following injection by flow analysis
using anti-CD4-FITC (Clone RM4-5), anti-CD3e-PE (Clone 145-2C11) and anti-CD8FITC (Clone 53-6.7). The control group of mice was inoculated with 200 µg of purified
normal rat IgG (Product number 14131-50mg, Sigma-aldrich).
Staining for myeloid derived suppressor cells (MDSCs): Female mice were injected
in the mammary gland with 7,000 4T1 cells. Twenty-one days later, splenocytes were
harvested in complete RPMI and passed through a 70 micron cell strainer. Splenocytes
were resuspended in 1× ACK buffer to lyse red blood cells. Splenocytes were stained
with 0.04% trypan blue to exclude dead cells and viable cell numbers were counted
under a light microscope using a hemocytometer. Splenocytes (1 × 106) were stained for
30 min with anti-mouse CD11b (PE-conjugated) and anti-Gr-1(PE/Cy5-conjugated)
(Biolegend, San Diego, CA). MDSCs in spleens were analyzed in BD FACS CantoTM II
flow cytometer.
Carboxyfluorescein diacetate, succinimidyl ester (CFSE) labeling: Splenocytes were
labeled by CFSE (CFSE cell proliferation kit for flow cytometry, Cat. No. C34554,
Invitrogen). Splenocytes were resuspended in 5 µM of CFSE in HBSS medium and
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Fig.2.1 Purification of anti-CD4 and anti-CD8 monoclonal antibodies using
hydrophobic charge induction chromatography with MEP HyperCel sorbent.
Selected fractions were subjected to SDS-PAGE gel under reducing conditions. Ig
heavy chain and light chain as well as truncated free light chain (TFLC) were labeled.
The majority of the truncated free light chain elutes at pH 3.0 and is highlighted in the
green box.
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incubated at room temperature for 5 min, then added 1 ml of inactivated fetal bovine
serum (FBS). Cells were centrifuged at 1,400 rpm for 5 min at 4°C and washed with
HBSS containing 10% inactivated FBS three times.
In vitro MDSC suppression of T cell proliferation: 96-well Plates were coated with
200 ul of 10 µg/mL of anti-CD3e (BD Pharmingen) and incubated for 24 h at 4°C, then
washed three times with PBS to remove any unbound antibody. Splenocytes (107
cells/mL in complete media) of naïve Tyk2+/+ and Tyk2-/- mice were used as responder
cells. Splenocytes from tumor-bearing Tyk2+/+ and tumor-bearing Tyk2-/- mice were
stained with anti-CD11b and anti-Gr1 serum and sorted to collect CD11b+Gr1+ cells
(MDSCs). Sorted MDSCs were incubated with CFSE-labeled naïve splenocytes in 1:2
ratio, directly to the culture medium in the presence of IL-2. Soluble anti-CD28
antibody (BD Pharmingen) was also added to the culture medium at 1 µg/mL. Cells
were plated at 2 × 105 cells/well and were allowed to proliferate for 48 h at 37°C, 5%
CO2. These cells were collected and blocked with anti-CD16/32. Cells were stained
with anti-CD3e and anti-CD4 or anti-CD3e and anti-CD8. CD4+ or CD8+ T cell
proliferation was monitored by flow cytometry for visualizing the decrease in CFSE
fluorescence by flow cytometry analysis.
Statistical analysis: Statistical analysis was performed using analysis of variance
(ANOVA) for tumor volume and metastatic disease. Data from multiple groups was
analyzed by ANOVA. For other data, differences between two groups were analyzed
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with the Student's t-test. Results of tumor growth are presented as the means ± standard
errors (SE) of tumor area in each group. In vitro assays were repeated three times. p <
0.05 was considered statistically significant.
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2.4 Results
Deletion of the Tyk2 gene promotes tumor growth and splenomegaly
Tyk2 plays an important role in host defense. It is reported that Tyk2 expression and its
signaling promotes invasiveness of prostate cancer cells in vitro without affecting
cellular growth rate (16). Another study reported that Tyk2-/- mice develop Abelsoninduced B lymphoid leukemia/lymphoma as well as Tel-Jak2–induced T lymphoid
leukemia with a higher incidence and shortened latency compared with Tyk2+/+ controls
(37). To determine the role of Tyk2 in breast cancer development, we used the 4T1
mouse mammary breast cancer model.
We were interested in whether the deletion of Tyk2 gene would regulate the onset and
outcome of breast cancer. To perform these studies, we used 4T1 mouse breast cancer
cells. Tyk2+/+ and Tyk2-/- female mice were inoculated in the abdominal mammary
gland with 7000 4T1 cells and tumor growth was monitored. At indicated times, tumor
volumes were measured. Tumor weights were measured when mice were sacrificed.
After 29 days of growth, a significant increase in tumor volume was observed in Tyk2-/mice compared with Tyk2+/+ mice (Fig.2.2(A)).

Tyk2 deletion caused a 3.5-fold

increase (p<0.0001) in tumor weight at 29 days after inoculation (Fig.2.2(B) and (C))
compared with Tyk2+/+ mice. These data indicate that Tyk2 deficiency in the host
immune system enhances primary tumor growth rates and final tumor weight compared
to Tyk2+/+ mice.
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Splenomegaly is a very common phenomenon in 4T1 cell tumor-bearing mice (10).
Therefore, we also examine whether the deletion of Tyk2 affects splenomegaly. Tyk2-/mice developed tremendously enlarged spleens compared to wild-type mice when
challenged to 4T1 tumor cells (Fig.2.3). A 4-fold increase was observed in the average
spleen weight in Tyk2-/- mice compared to wild-type mice (p < 0.0001) at 29 days after
inoculation.
Tyk2-deficient mice have increased metastatic disease
4T1 tumors spontaneously metastasize from the primary tumor in the mammary gland
to multiple distant sites including lymph nodes, liver, lung, brain, and bone. 4T1 cells
are resistant to 6-thioguanine. This property enables precise quantification of metastatic
cells, even when they are disseminated and are present at microscopic levels in distant
organs. To determine the effect of Tyk2 deletion on metastasis of breast cancer, Tyk2+/+
and Tyk2-/- female mice were inoculated with 4T1 cells. 29 days after inoculation, mice
were sacrificed. Lungs and livers were collected and clonogenic assays were performed.
The number of colonies in Tyk2-/- lungs is significantly greater than in Tyk2+/+ mice
(Fig.2.4(A)). A similar pattern was seen in livers (Fig.2.4(B)).
Tyk2-/- mice develop increased metastastic disease. There are two possible causes. First,
there is a larger primary tumor in Tyk2-/- mice. Second, Tyk2 deficiency in the host. To
rule out the effect of the primary tumor on metastasis, Tyk2+/+ and Tyk2-/- female mice
were inoculated with 4T1 tumor cells by tail vein injection. 10 days after inoculation,
lungs and livers were collected and metastatic disease was measured by clonogenic
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Fig.2.2 The deletion of Tyk2 gene promotes tumor growth

Tyk2+/+ and Tyk2-/-

female mice were inoculated with 4T1 cells in the abdominal mammary gland and
followed for tumor growth. (A) Tumor volumes. Tumor growth was monitored at
indicated times and measured in two dimensions using Vernier calipers. (B) Primary
tumors and (C) tumor weights. 29 days after inoculation, mice were sacrificed and
primary tumors were collected and weighted (p <0.0001). Each group has 12 mice. Data
bars represent the mean ± standard errors. These data are pooled from two experiments.
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Fig.2.3 Deletion of Tyk2 promotes splenomegaly induced by 4T1 tumor cells
Tyk2+/+ and Tyk2-/-

mice were inoculated with 7000 4T1 cells in the abdominal

mammary gland. 29 days after inoculation, mice were sacrificed and spleens were
collected and weighted. (p < 0.0001). (A) Spleens from naïve mice and tumor-bearing
(TB) Tyk2+/+ and Tyk2-/- mice. (B) Spleen weights. Data bars represent the mean ±
standard errors. These data are pooled from two experiments.
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assay. The number of colonies in Tyk2-/- lungs was significantly greater than those in
Tyk2+/+ lungs (Fig.2.5 (A)). Similar result was seen in livers (Fig.2.5 (B)). These data
suggests that Tyk2 deficiency in the host is less resistant to metastastic spread of tumor
cells.
Tyk2-/- mice produce less IFNγ than Tyk2+/+ mice
IFNγ plays important roles in antitumor immunity (18, 20, 32, 38). Impaired IFNγ
production in Tyk2-/- NK cells has been shown to be a major mechanism by which
Tyk2-/- mice develop Abelson-induced B lymphoid leukemia/lymphoma as well as TelJak2–induced T lymphoid leukemia (37). The CD8+ T cell response in Tyk2-/- mice is
characterized by decreased levels of both cytolysis and IFNγ production when the mice
are challenged with Listeria monocytogenes (19, 21). Therefore, we hypothesized that
decreased IFNγ production might be involved in enhanced tumor growth of Tyk2-/- mice.
To examine the effect of Tyk2 deficiency on IFNγ production, Tyk2+/+ and Tyk2-/female mice were inoculated with 4T1 cells in the mammary gland. After 5 days,
spleens were harvested. Splenocytes (5 x106) were then cocultured with IL-2 in
complete medium in the presence or absence of irradiated 4T1 cells (4x105) (15000
rads). After 24 h of incubation, the supernatants were collected and IFN-γ concentration
in the supernatants was determined using a Mouse IFN-γ ELISA kit. As shown in Fig.
2.6, Tyk2-/- mice produce lower levels of IFN-γ than WT mice. The differences in basal
IFN-γ and 4T1–induced IFN-γ production were statistically significant (P ≤ 0.005).
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Fig.2.4 Tyk2-/- mice have increased metastasic disease

Tyk2+/+ and Tyk2-/- female

mice were inoculated with 7000 4T1 cells in the abdominal mammary gland. 29 days
after inoculation, mice were sacrificed and livers and lungs were collected. (A) Lung
metastatic disease. (B) Liver metastatic disease. Each group contained twelve mice.
These data are pooled from two experiments.
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Fig.2.5

Tyk2 deficiency in the host promotes metastasis. Female mice were

inoculated with 4T1 cell by tail vein injection. After 10 days, lungs and livers were
collected. Metastasis were measured by clonogenesis assay. (A) Metastatic colonies of
lungs. (B) Metastatic colonies of livers. Each group had eight mice.
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Fig. 2.6 Tyk2-/- splenocytes produce less IFNγ than Tyk2+/+ splenocytes Female
mice were inoculated with 4T1 cells. After 5 days, spleens were harvested. Splenocytes
(5x106) were then cocultured with IL-2 in the presence or absence of irradiated 4T1
(4x105 cells) (15000 rads). After 24 h, the supernatants were collected. IFN-γ
concentration in these supernatants was determined using a Mouse IFN-γ ELISA kit.
Data bars represent means and standard errors.
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Tyk2-/- NK cells do not contribute to the enhanced tumor growth in Tyk2-/- mice
NK cells are the first defense of the host against tumor cells. Tyk2-/- NK/NKT cells have
been reported to display defects in both IFNγ production and cytolytic activity in tumor
surveillance in Abelson-induced malignancies (37). Our data also demonstrate that
Tyk2-/- mice produce less IFNγ than Tyk2+/+ mice. NK cells also produce IFNγ.
Therefore, we examined whether Tyk2-/- NK cells contribute to the enhanced
susceptibility of Tyk2-/- mice by in vivo depletion of NK cells. Recipient mice were
intraperitoneally (i.p.) injected with 200 µg of rabbit anti-asialo GM1 or control rabbit
IgG serum before tumor inoculation. Antibody injections were performed on day 0, 1, 7,
11, 14 and 20, where day 1 is also the day of tumor challenge (Fig.2.7 (A)). The control
group of mice was injected with the same amount of purified normal rat IgG. NK cells
(CD3-DX5+) were measured to confirm the depletion by flow cytometric analysis of
peripheral blood lymphocytes (Fig.2.7 (B)). Before the depletion, both Tyk2+/+ and
Tyk2-/- mice have about 5-7% NK cells. After NK cell depletion, they have about 0.1%
NK cells, indicating that NK cell depletion was efficient.
Tumor volume in Tyk2+/+ mice is significantly increased after NK cell depletion and
similar pattern was seen in Tyk2-/- mice (Fig.2.8 (A)), suggesting that NK cells are
critical to control tumor growth in both Tyk2+/+ and Tyk2-/- mice. However, the tumor
volume difference between NK-depleted and IgG groups in Tyk2+/+ mice was similar to
that in Tyk2-/- mice (Fig.2.8 (B)), suggesting that NK cell control of tumor growth is
equivalent in Tyk2+/+ and Tyk2-/- mice. Our data indicates that NK depletion alone does
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Fig.2.7 The schedule of NK cell depletion and the efficiency of the depletion
Recipient mice were injected with 200 µg of rabbit anti-asialo GM1 or control rabbit
serum before tumor inoculation. Antibody injections were performed on day 0, 1, 7, 11,
14 and 20, where day 1 is also the day of tumor challenge. The control group of mice
was inoculated with the same amount of purified normal rat IgG. (A) The schedule of
NK cell depletion. Ab – antibody or nonspecific IgG. FC – flow cytometry analysis. (B)
The efficiency of NK cell depletion by flow cytometry analysis. Blood was lysed with
1xACK buffer to remove red blood cells and then stained with anti-CD3e –PE and antiDX5-FITC.
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not contribute to increased tumor growth in Tyk2-/- mice, suggesting that other
components are altered that account for increased tumor growth of Tyk2-/- mice.
Tyk2-/- CD8+ T cells alone do not contribute to the enhanced tumor growth in
Tyk2-/- mice
Tyk2-/- mice are defective in response in IL-12 which is essential for development of
CD4+ Th1 cells, and thus preferentially produce CD4+ Th2 cells. Th1 cells are generally
considered to activate CD8+ T cells, whereas Th2 cells activate antibody-producing B
cells. Th1 cells are proposed to facilitate differentiation of tumor-specific CD8+ T cells,
which are potent anti-tumor effectors. In addition, splenocytes from tumor-bearing
Tyk2-/- mice also produce less IFNγ, consistent with Th2 phenotype of Tyk2-/- mice. In
addition, CD8+ T cells are a major tumor cell killer and critical for 4T1 tumor rejection
in Stat6-/- mice (30). Therefore, we hypothesize that Tyk2-/- mice have increased
susceptibility to 4T1 tumor cells because differentiation of CD4+ T cells would be
skewed toward a Th2 response. To identify the T effector cells responsible for the
enhanced tumor burdens of Tyk2-/- mice, mice were in vivo depleted of CD4+ or CD8+ T
cells before tumor cell inoculation into the mammary gland. In vivo T-cell depletion was
performed using purified monoclonal antibodies against anti-CD4 (GK1.5) or anti-CD8
(2.43). Mice were in vivo depleted for CD4+ or CD8+ T cells by i.p. injection of 200 ug
MAb before tumor inoculation. Antibodies were injected on days 1, 6, 13, where day 2
was the day of tumor challenge (Fig.2.9 (A)). The presence of CD4+ or CD8+ T cells
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Fig.2.8 Tyk2-/- NK cells do not contribute to enhanced susceptibility of Tyk2-/- mice
Experimental detail as described in Fig.2.7. (A) Tumor volume (mm3) at 23 days after
inoculation. (B) Tumor volume difference between NK-depleted and IgG group. Data
bars represent the mean ± standard errors. Each NK cell depleted group had eight mice,
other groups had six mice. * represents p < 0.001.

55

were examined on the following day by flow analysis using anti-CD4-FITC (Clone
RM4-5), anti-CD3e-PE (Clone 145-2C11) and anti-CD8-FITC (Clone 53-6.7). The
control group of mice was inoculated with purified normal rat IgG.

Before the

depletion, both Tyk2+/+ and Tyk2-/- mice have about 6-8% CD8+ ,13-15% CD4+ cells
(Fig.2.9(B)). After depletion, they have about 0.1% CD8+ or CD4+ cells (Fig.2.9 (C)),
indicating that both CD8+ cell depletion and CD4+ T cell depletion were efficient.
Surprisingly, in vivo depletion of CD4+ T cells does not influence tumor growth rate
(Fig.2.10), indicating that CD4+ T cells are not required for enhanced susceptibility of
Tyk2-/- mice. This result supports that CD4+ T cells are not involved in enhanced
immunity of Stat6-/- mice when challenged with 4T1 cells.
Tumor volume in Tyk2+/+ mice is significantly increased in Tyk2+/+ mice after CD8+ T
cell depletion and similar pattern was seen in Tyk2-/- mice (Fig.2.11 (A)), suggesting
that CD8+ cells are critical to control tumor growth in both Tyk2+/+ and Tyk2-/- mice.
However, the tumor volume difference between CD8+-depleted and IgG groups in
Tyk2+/+ mice was similar to that in Tyk2-/- mice (Fig.2.11 (B)), suggesting that CD8+
cell control of tumor growth is equivalent in Tyk2+/+ and Tyk2-/- mice.
Tumor-bearing Tyk2-/- mice have increased number of myeloid derived suppressor
cells (MDSCs) than Tyk2+/+ mice
MDSCs are immature cells that are in the process of differentiating into mature
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Fig.2.9 The schedule of CD8+ and CD4+ T cell depletion and the efficiency of the
depletion

Female mice were challenged with 4T1 tumor. Antibody injections were

performed on day 1, 6, 13. On day 2, mice were inoculated with 4T1 cells. The control
group of mice was inoculated with the same amount of purified normal rat IgG. (A) The
schedule of T cell depletion. Ab – antibody or nonspecific IgG. FC – flow cytometry
analysis. (B) Before T cell depletion. (C) After depletion.
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Fig.2.10 Depleting CD4+ T cells does not impact 4T1 tumor growth Experimental
details as described in Fig.2.9. Tumor volume (mm3) at 19 days after inoculation. Data
bars represent the mean ± standard errors. CD4+ T cell depleted group had eight mice,
other groups had six mice. * represents p < 0.001.
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Fig.2.11 CD8+ T cells do not contribute to increased primary tumor growth in
Tyk2-/- mice Experimental details as described in Fig.2.11. (A) Tumor volume (mm3)
at 19 days after inoculation. (B) Tumor volume difference between CD8-depleted and
IgG group. Data bars represent the mean ± standard errors. CD8+ T cell depleted group
had eight mice, other groups had six mice. * represents p < 0.0001.
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granulocytes, dendritic cells, or macrophages and are identified by their expression of
Gr1 and CD11b. MDSCs frequently accumulate in patients and experimental animals as
tumor burden increases, resulting in immune suppression by inhibiting T cell function
(28). 4T1 tumor-bearing BalB/c mice exhibit a progressive granulocytosis (10).
Splenomegaly in 4T1 tumor-bearing mice is correlated with a striking increase in
immature splenic granulocytes (25). To determine whether the deletion of Tyk2–/– gene
affects MDSC levels in 4T1 tumor-bearing mice, wild-type and Tyk2–/– mice were
inoculated in the mammary gland with 4T1 tumor cells, and splenocytes were harvested
22 days later, stained, and analyzed by flow cytometry for CD11b+Gr1+. Tumor-free
WT and Tyk2–/– mice had similar levels of MDSC in spleens, whereas tumor-bearing
Tyk2-/- mice had elevated levels of MDSC (Fig.2.12).
To determine whether Tyk2 deficiency influences the function of MDSCs to suppress T
cell proliferation, Tyk2+/+ and Tyk2-/- mice were inoculated 7000 4T1 tumor cells. 17
days after inoculation, spleens were harvested and stained with anti-CD11b and antiGr1. MDSCs were collected by sorting CD11b+Gr1+ cells and incubated with CFSElabeled naïve splenocytes for 2.5 days. After incubation, cells were stained with antiCD3-PE and anti-CD4-PE/Cy5 or anti-CD8a-PE.Cy5. CD4+ and CD8+ T cell
proliferation were measured by checking CFSE changes. MDSCs did suppress T cell
proliferation compared to positive controls. Tyk2-/- MDSCs have a slight increase in
suppression of CD4+ T cells (Fig.2.13 (B)). A similar pattern was seen in suppression of
CD8+ T cells (Fig.2.13(C)).
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Fig.2.12 Tumor-bearing Tyk2-/- mice have higher levels of MDSCc than tumorbearing Tyk2-/- mice. Mice were inoculated with 4T1 cells. At 22 days after inoculation,
spleens were harvested and splenocytes were stained for MDSCs. Each group had three
mice. Each group has three mice. Data bars represent the mean ± standard deviation.
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Fig.2.13 Tyk2-/- MDSCs have a slight increase in suppressing T cell proliferation
Tyk2+/+ and Tyk2-/- mice were inoculated 7000 4T1 tumor cells. 17 days after
inoculation, splenocytes were harvested and stained with anti-CD11b and anti-Gr1.
MDSCs were collected by sorting CD11b+Gr1+ cells and incubated with naïve
splenocytes labeled with CFSE. After incubation, cells were stained with anti-CD3-PE
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and anti-CD4-PE/Cy5 or anti-CD8a-PE.Cy5. CD4+ and CD8+ T cell proliferation were
measured by checking CFSE changes. (A) Negative control and positive control. (B)
Suppression on CD4+ T cells. (C) Suppression on CD8+ T cells.
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2.5. Discussion
Aberrant activation of Jak/Stat pathway has been observed in many human cancers (2, 3,
5, 6, 7, 9, 12). Jaks transform cells upon constitutive activation. For example, Jak1 has
been involved in malignant transformation by the v-abl as well as by the v-src oncogene
(7, 42), and abnormal fusion of Tel to Jak2 results in constitutive activation of Jak2,
which induces leukemia in mice and humans (5, 25). Constitutive activation of Jak1 and
Jak2 also has been shown in mouse T cell lymphomas. It is reported that Tyk2
expression and its signaling promotes invasiveness of prostate cancer cells in vitro
without affecting cellular growth rate (16). However, Jak1 was shown to be a tumor
suppressor downstream of IFN-γ in a B lymphoid tumor model (38). In addition, Tyk2-/mice are reported to develop Abelson-induced B lymphoid leukemia/lymphoma as well
as Tel-Jak2–induced T lymphoid leukemia with a higher incidence and shortened
latency compared with WT mice (37). In view of these interesting studies, we
investigated the role of Tyk2 in the pathogenesis of breast cancer. To investigate the
role of Tyk2 in the breast cancer, we used the 4T1 mouse mammary system which
closely models human breast cancer.
Our experiments show that Tyk2-/- mice have a 3.5-fold increase in average tumor
weight, and a 4-fold increase in spleen weights than WT mice when inoculated with
4T1 cells. This observation is opposite to the findings that Tyk2 expression and
signaling enhances the invasiveness of prostate cancer cells (16), but supports that the
findings that mice
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deficient in Tyk2 develop Abelson-induced B cell leukemia with higher incidence and
shortened latency compared with Tyk2+/+ mice (37).

We also found that Tyk2

deficiency promotes metastasis of 4T1 cells.
Tumor development is a battle between the host immune system and the evolving tumor.
IFNγ is considered to be a key component in tumor surveillance (18, 20, 32, 38) and is
pivotal for Th1 differentiation. IFNγ production in Tyk2-/- mice was significantly lower
than Tyk2+/+ mice. It is consistent with the findings of impaired IFNγ production in
Tyk2-/- NK cells in the Abelson-induced B leukemia model as well as decreased levels
of IFNγ production in Tyk2-/- CD8+ T cell when challenged with Listeria
monocytogenes (21).
NK cells are the first line of defense against tumor. Tyk2-/- NK/NKT cells have been
reported to be a key regulator in surveillance of B lymphoid tumors (37). In vivo
depletion of NK cells shows that NK cells are essential for tumor rejection, but Tyk2-/NK cells are not the cause of the increased tumor burdens with seen in Tyk2-/- mice. Our
findings contrast with those that indicated that Tyk2-/- NK cells enhance the
development of B cell leukemias and T cell leukemias (37). Our results indicated that
the effect of NK/NKT cells in tumor surveillance depends on the origin of the tumor
cell and varies among individual tumor types. Our data shows that NK cells are not
involved in metastasis.
Because NK cells do not contribute to enhanced susceptibility of Tyk2-/- mice, the
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deletion of the Tyk2 gene must reduce tumor immunity via a mechanism independent of
NK cells. Besides NK/NKT cells, T cells are thought to play important in tumor
rejection. Tyk2 is required for IL-12 actions, a cytokine essential for developing Th1
cells. CD4+ T cell responses in Tyk2-/- mice are strongly skewed toward a Th2 response.
Surprisingly, however, in vivo depletion of CD4+ T cells does not influence tumor
growth in both Tyk2+/+ and Tyk2-/- mice, indicating that CD4+ T cells are not involved
in enhanced tumor burdens in Tyk2-/- mice. Therefore, the Tyk2 effect is not due to an
increase in tumor-specific Th2 cells, as originally hypothesized. The lack of
involvement of CD4+ T cells is also supported by the finding that depletion of CD4+ T
cells does not impact tumor growth in Stat6-/- mice (30).
In vivo depletion of CD8+ T cells shows that CD8+ T cell control of tumor growth is
equivalent in Tyk2-/- and Tyk2+/+ mice. This suggests that Tyk2-/- CD8+ T cells alone do
not contribute to enhanced tumor growth in Tyk2-/- mice. These data is not consistent
with the observation that reduced primary 4T1 and metastatic tumor growth is mediated
by CD8+ T cells in Stat6-/- mice (30) and that Tyk2-/- mice showed a reduced CD8+ CTL
responses following infection with lymphocytic choriomeningitis virus (21), IL-12induced IFN-γ production by CD8+ T cells was strongly suppressed in Tyk2-/- mice
infected with Leishmania major (21).
In vivo depletion of NK or CD8+ T cells shows that neither Tyk2-/- NK cells alone nor
CD8+ T cells alone are not responsible for enhanced tumor growth in Tyk2-/- mice when
challenged with 4T1 tumor cells.
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These results are consistent with our bone marrow reconstitution data (not shown).
Tyk2-/- and Tyk2+/+ reciprocal bone marrow chimeras do not have decreased
immunosurveillance, demonstrating that enhanced susceptibility requires Tyk2-/nonhemopoietic components.
MDSCs suppress T cell function and accumulate in tumor bearing patients and mice as
tumor burdens increase (28). Our data show that tumor-bearing Tyk2-/- mice have
higher levels of MDSCs than tumor-bearing Tyk2+/+ mice, consistent with the fact that
Tyk2-/- mice develop larger tumors than Tyk2+/+ mice. Tyk2-/- MDSCs have a slight
increase in suppression of T cell proliferation.
Tyk2-/- mice display impaired IFNα/β signaling which plays a role in antitumor
immunity. In the future experiments, we will determine whether a deficit in IFNα/β
signaling is responsible for increased tumor growth in Tyk2-/- versus Tyk2+/+ by
examining the effect of blocking IFNα/β receptor signaling on tumor growth in Tyk2+/+
and Tyk2-/- mice. In addition, Tyk2-/- DCs are impaired in their ability to induce Th1cell differentiation but not Th2-cell differentiation in response to IL-12. Th1 cytokines
suppress Th17 differentiation. This suggests that Tyk2-/- mice might develop elevated
Th17 cells in response to IL-12. Th17 is known to promote tumor growth. We will
examine whether differences in Th1/Th2/Th17 balance underlie differences in tumor
growth between Tyk2-/- and Tyk2+/+ mice. We will deplete IFNγ, IL-4, or IL-23 and IL17 and examine the effects of their depletion on tumor growth. Moreover, we will
examine whether a deficit in antigen presentation by tumor cells or APCs explains the
differences in tumor growth between Tyk2-/- and WT. So we plan to compare MHC
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Class I and II levels on tumor and antigen presenting cells (APCs) in Tyk2-/- and
Tyk2+/+ mice. Furthermore, since Tyk2-/- splenocytes have increased MDSC levels. So
we want to examine whether Tyk2 deficiency increases MDSC development
independent of tumor size. We will compare MDSC numbers and percentages in Tyk2-/and Tyk2+/+ mice with equivalent tumor size.
Our study demonstrates that deletion of Tyk2 gene promotes breast cancer growth and
metastasis. Depletion of Tyk2-/- CD8+ T cells slows metastastatic growth. The enhanced
susceptibility of Tyk2-/- mice requires both hematopoietic and nonhematopoietic cells.
Neither Tyk2-/- NK cells, nor Tyk2-/- CD8+ T cells alone contribute to the increased
tumor burdens in Tyk2-/- mice. Our study supports the concept that Tyk2 deficiency in
the host predisposes to tumor formation. We speculate that important regulators of Tyk2
activity will be targets for future therapies.
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Chapter III

Mitochondrial-localized Stat3 (MLS Stat3)

Mediates breast cancer development and protects tumor cells
from hypoxia
3.1 Abstract
Signal transducer and activator of transcription 3 (Stat3) is a latent cytoplasmic
transcription factor that is activated in response to cytokines and oncogenes. In this
study, we explored the role of mitochondrial-localized Stat3 in the pathogenesis of
breast cancer. Stat3 and its various variants were targeted to mitochondria in 4T1 breast
cancer cells. We report that expression of mitochondrial-localized Stat3 Y705F/S727A
(MLS Stat3 Y705/S727A) inhibits the ability of these cells to grow and metastasize. In
contrast, the MLS Stat3 Y705F/S727D mutant enhances transformation and
tumorigenesis. Moreover, MLS Stat3 protects these tumor cells from hypoxia-induced
ROS accumulation. Taken together, these results suggest that MLS Stat3 mediates the
pathogenesis of breast cancer by regulating ROS production.

3.2 Introduction
Signal transducers and activators of transcription proteins (Stats) are a family of latent
cytoplasmic transcription factors that play a critical role in the biological actions of
many cytokines (24, 27-30, 35, 42). In mammals, seven Stat members have been
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identified: Stat1, Stat2, Stat3, Stat4, Stat5a, Stat5b and Stat6 (24, 30, 42). Upon
cytokine or growth factor stimulation, Stats are activated by tyrosine phosphorylation,
then dimerize and translocate to the nucleus and regulate expression of genes involved
in cell growth, development, survival, differentiation, apoptosis and immune function
(30, 42).
Stat3 was initially identified as the acute-phase response factor (APRF), activated by
interleukin (IL)-6 (1, 43). Stat3 is essential for mammary development. When lactation
terminates, leukemia inhibitory factor (LIF) activates Stat3, resulting in involution of
the mammary gland allowing for tissue (12, 13). Stat3 deficient mammary glands show
decreased apoptosis and a dramatic delay of involution. Constitutively activated Stat3
has been observed in many human cancers (6, 16, 18, 19, 22, 23, 40). Inhibition of Stat3
activity blocks tumor growth (8, 11, 32). Clinical studies demonstrated that increased
levels of Stat3 phosphorylation in patients with stage II breast cancer correlated with an
incomplete response to neo-adjuvant chemotherapy (23) and was also associated with
metastasis in regional lymph nodes (19).
Although constitutive tyrosine phosphorylation of Stat3 has been implicated in the
pathogenesis of many malignancies, there are a number of studies indicating that
phosphorylation of serine 727 of Stat3 is also involved in cell survival and cellular
transformation. Overexpressed Stat3 S727A was reported to exert a dominant–negative
effect on v-Src-mediated transformation (5). Patients with chronic lymphocytic
leukemia (CLL) expressed constitutive serine phosphorylation of Stat3 in the absence of
tyrosine phosphorylation of the protein (4, 17). Serine phosphorylation of Stat3 was
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observed in all patients with CLL and was absent in normal peripheral blood B
lymphocytes. Stat3 Y705F/S727E mutant which does not have transcription activity
promotes prostate tumorigenesis (40). Furthermore, 65% of primary human prostate
cancers displayed constitutive serine phosphorylation of Stat3 (39). The role of Stat3
serine 727 in tumor growth and invasion of these tumor cells remains unclear.
Our recent studies demonstrate that Stat3 localizes in the mitochondria and regulates
complex I, II and V of the electron transport chain (44) . Serine 727 phosphorylation of
Stat3 is required for its function in the mitochondria. In addition, the ablation of Stat3
abrogates H-Ras transformation of MEFs (21). Targeting of Stat3 to the mitochondria
restores the ability of H-Ras transformed mouse embryonic fibroblasts (MEFs) to grow
tumors in mice (21).
Gene associated with retinoid-interferon-induced mortality (Grim19) is a subunit of
complex I of the electron transport chain in mitochondria (10, 15, 38) and is essential
for breast cancer cell death induced by IFNβ and retinoic acid (RA) (3). Grim19
interacts with Stat3 and inhibits Stat3 activity, and serine 727 phosphorylation of Stat3
is required for this interaction (34, 45). It is reported that Stat3-/- hearts show elevated
levels of ROS (25). Complex I is a major source of ROS production (37). Therefore,
we hypothesize that mitochondrial localized Stat3 mediates the pathogenesis of breast
cancer through its actions in regulating ROS production.
In this study, we investigated whether mitochondrial-localized Stat3 mediates the
development of breast cancer.

We used the 4T1 mouse breast cancer model which

mimics the pathology of human breast carcinomas in that the cells form large primary
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tumors which metastasize to many distant organs. Various forms of Stat3 with a
mitochondrial localization sequence were stably expressed in 4T1 cells. Under normal
conditions of cell culture, expression of MLS Stat3 and its variants did not influence
cell growth rates. However, under glucose starvation, the cellular growth rates were
significantly impaired in cells expressing MLS Stat3 Y705F/S727A, whereas expression
of MLS Stat3 Y705F/S727D promoted celluar growth. Similar effects were seen with
expression of these forms of MLS Stat3 in transforming activity, invasion ability and
tumorigenesis of cells. Finally, we show here that MLS Stat3 YFSA and SA mutants
had higher levels of protein tyrosine nitration under hypoxia, whereas MLS Stat3 YFSD
had the lowest level of protein tyrosine nitration. In conclusion, MLS Stat3 promotes
breast cancer growth by protecting tumor cells from hypoxia.
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3.3 Materials and methods
Cell culture: The 6-thioguanine-resistant 4T1 mouse mammary carcinoma cell line was
obtained from the American Type Culture Collection (Rockville, MD). Cells were
grown in DMEM (Invitrogen) medium supplemented with 10% fetal bovine serum
(Serum Source International INC., Charlotte, NC), 1.0 mM sodium pyruvate (optional),
100 U/mL penicillin, and 100 µg/mL streptomycin (Mediatech INC., Hemdon, VA).
Mice were subcutaneously injected in the mammary gland with 7.0 × 103 4T1 cells in
1x PBS.
Mice: BALB/c mice were purchased from the Jackson Laboratory (Bar Harbor, ME).
The mice were housed in a ventilated barrier rack (Lab Products, Inc., Seaford, DE) in a
temperature-controlled facility on a 12-h photoperiod. This research was conducted
under a protocol approved by Virginia Commonwealth University IACUC Review
Board.
Antibodies and Reagents: Mouse monoclonal Stat3-specific antibodies were
purchased from BD Transduction Laboratories. 30 KDa Complex II subunit VIII (MS
203) antibody was purchased from Mito Sciences. Antibodies were used at a final
dilution of 1:1000. Mouse monoclonal anti-α-tubulin was purchased from Sigma and
used at a 1:5000 dilution. Murine recombinant oncostatin M (Cat.No. 1637) was
purchased from Sigma. Anti-nitro-tyrosine antibody (Cat.No. 06-284) was purchased
from Milipore. Anti-actin antibody (Cat. No. sc-56459) was purchased from Santa-Cruz.
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Mutagenesis: SH2 mutations in MLS Stat3 Y705F/S727A and Stat3 Y705F/S727D
constructs were generated using the Chameleon mutagenesis kit ( Stratagene ). The
following primers were used to generate the arginine (R609) to glutamine (Q) mutation:
forward primer: 5’-C CCG GGT ACC TTC CTA CTG CAG TTC AGC GAG AGC
AGC AAA G-3’, reverse primer: 5’- T GAA CTG CAG TAG GAA GGT ACC CGG
GGG CTT TGT GC-3’. All mutations were sequenced to verify mutations.
Transfection and Infection: The empty vector (MSCV-IRES-GFP) and the vectors
encoding wild type Stat3 and different MLS mutants of Stat3 were transfected into 293
T cells with Phoenix helper vector using Fugene transfection reagent (Roche). Viruscontaining medium was collected at 48 h and used to infect 4T1 cells. The cells
expressing GFP, following 8 to 10 days of infection, were sorted by FACS (>95% GFP+)
and used for experiments.
Preparation of whole cell extracts:

The 4T1 cells were washed with 1x PBS,

collected by centrifugation at 500 xg at 4 °C for 5 min. Cell pellets were resuspended
and lysed using ice-cold whole cell extraction buffer (20 mM Hepes, 300 mM NaCl, 10
mM KCl, 1 mM MgCl2, 20% glycerol, 1% NP-40, 0.5 mM dithiothreitol, 10 mM bglycerophosphate, 200 µM PMSF, 25 mM NaF and 1 mM sodium orthovanadate). Cell
debris was removed from the lysates by centrifuging the samples at 20,000 xg for 30
min at 4 °C. The protein concentration was determined using the Bradford protein assay
(Bio-Rad).
Isolation of mitochondria and preparation of cytosolic and mitochondrial lysates:
Intact mitochondria were isolated from 4T1 cells and 4T1 cells expressing different
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MLS mutants using differential centrifugation as described by Gasnier et al (20). Cells
were harvested, washed once with cold PBS, and resuspended in ice-cold sucrose buffer
(20mM HEPES pH 7.4, 250mM sucrose, 1mM EDTA, 1mM PMSF, 5µg/ml aprotinin,
1µg/ml leupeptin, 25mM NaF, 1mM sodium vanadate ). Cells were then homogenized
and unbroken cells and nuclei were removed by centrifugation at 1000 x g for 5 min at
4°C. Supernatants were centrifuged at 1000 x g for 5 min at 4 °C twice. The
supernatants were further centrifuged at 7700 x g for 10 min at 4°C to obtain the crude
mitochondrial fraction. The supernatants resulting from the above step were subjected
to a high-speed centrifugation at 100,000 x g for 1 h at 4°C to obtain the cytosolic
fraction. The crude mitochondrial pellet was washed with ice-cold Sucrose buffer four
times to remove cytosolic contamination. To purify mitochondria, crude mitochondria
werer resuspended in cold Sucrose buffer and layered on the top of a 2.5 M sucrosepercoll gradient and centrifuged at 46,000 x g for 45 min at 4°C. The mitochondria
were collected and washed twice with Sucrose buffer at 7700 x g for 10 min at 4°C. The
mitochondria were resuspended in Sucrose buffer and protein concentration of both
mitochondrial and cytosolic lysates was determined using the Bradford dye-binding
protein assay (Bio-Rad). Then mitochondria were frozen at -80°C for 1 h, lysed in 2x
SDS sample buffer and boiled at 95 °C for 8 min.
Western blot analysis: Total cell lysates, cytosolic, or mitochondrial lysates were
subjected to 10%

SDS-PAGE. Proteins were transferred to an Immobilon-P

polyvinylidene difluoride (PVDF) membrane (Millipore). The membranes were blocked
in 5% milk, 1xTBS-T buffer (20mM Tris-HCl pH 7.5, 500mM NaCl, 0.05% Tween 20)
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for 1 h at room temperature. The membranes were incubated with the primary antibody
diluted in TBS-T buffer for 2 h at room temperature followed by 3 washes with TBS-T.
The blots were incubated with 1:5000 dilution of the-conjugated secondary antibody
(Zymed) for 1 h followed by 3 washes with TBS-T. Immunoblots were developed with
IRDye 700DX conjugated Anti-mouse IgG (H&L) (Donkey), Cat. No. 610-730-124).
Reverse Transcription Polymerase Chain Reaction (RT-PCR) Assay and
quantitative RT-PCR: Total RNAs were isolated with Trizol reagent (Invitrogen) from
untreated 4T1 cells and 4T1 cells expressing MLS Stat3 and variants, some cells were
placed in serum-free media for 3 hrs and then treated with murine oncostatin (500 ng/ml)
for 4 hrs. 2 µg of total RNA from the respective samples were used to generate cDNA
using the Bioline cDNA synthesis kit. RNA C/EBPδ expression was determined by
real-time PCR using SYBR Green PCR master mix kit (Applied Biosystems).
Quantitative RT-PCR analysis was performed using an C1000TM Thermal Cycler (BIORAD) according to the manufacturer’s specifications. For cDNA-specific genes, all
samples were run in duplicate, and amplification data were analyzed using CFX
ManagerTM software, version 1.1.308.111. Relative quantification was calculated
according to the

Ct method using a statistical confidence of 99.9%. β-actin RNA

concentrations were measured as an internal control. C/EBP δ forward primer: 5’CTCCCGCACACAACATACTG-3’,

reverse

primer:

5’-

CTTCGGCAACCACCTAAAAG-3’. The following primers were used to analyze the
β-actin cDNA levels – 5’- GGT CAT CAC TAT TGG CAA CG-3’ (forward), 5’-ACG
GAT GTC AAC GTC ACA CT-3’ (reverse).
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Cell growth assay: 35,000 cells were plated per well in 12 well plates in complete
media and cultured in 5% CO2 with normal oxygen in humidified incubator at 37 °C
for 24 h, 48 h or 72 h. Cells were harvested and counted using Particle Count & Size
Analyzer Z2 ( Coluter).
MTT assay: Colorometric dimethyl-thiazol-diphenyltetrazolium bromide (MTT)
proliferation assay was performed in a 96-well plate in triplicate using MTT
proliferation assay kit ( Promega Cat. No. G3580). Cells at 85–100% confluence were
harvested with 1x trypsin/EDTA solution and seeded into a 96-well plate at 4 x 103
cells/well. Triplicates of each cell line were plated. 20 ul of CellTiter 96®Aqueous One
Solution Reagent was added to each well and incubated for 3 h in a 37 °C cell culture
incubator. The ODs in the 96-well plates were determined at 490 nm in a microplate
reader (Molecular Devices, Sunnyvale, CA).
Glucose starvation assay: 35000 cells were seeded in triplicate per well in 12 well
plates in DMEM containing 0.5 g/L glucose and cultured in 5% CO2 with normal
oxygen in humidified incubator at 37 °C for 48 h or 72 h. Cells were collected and cell
numbers were calculated by Coulter counter. Independent experiments were repeated
three times.
Soft agar assay: Cells (1 × 103) were seeded in triplicate in 0.35% low-melting agar in
60-mm dishes, prepared in standard growth media. Cells were cultured in a humidified
incubator at 37 °C and 5% CO2 for 10-12 days. Colonies greater than 0.2 mm2 were
scored. Independent experiments were performed in triplicates.
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Matrigel Invasion assay: Tumor cell invasion assays were done using 24-well BioCoat
cell culture inserts ( BD BioCoat™ Matrigel™ Invasion Chambers, Cat. No. 354480,
Becton Dickinson Labware, Bedford, MA) with 8-µm porosity polyethyleneterepthylate
membranes coated with Matrigel. Briefly, cells (5 x 103 in 500 µL serum-free medium)
were seeded in triplicate in inserts in the wells containing complete medium. Cells were
incubated at 37°C for 22 hrs. After incubation, the non-invading cells are removed from
the upper surface of the membrane by gentle “scrubbing”. The cells on the lower
surface of the membrane were stained with Diff-Quik kit (Cat. No. K7128). Migration
was determined by counting cells that had migrated to the lower side of the filter with a
microscope at x100 magnification. Experiments were done in triplicate, and at least
eight fields were counted in each experiment.
Measurement of tumor growth: Tumor growth was assessed morphometrically using
Calipers, and tumor volumes were calculated according to the formula V (mm3) = L
(major axis) × W2 (minor axis) / 2 (9). Experiments were terminated when the tumors
reached an average diameter of 16 mm or when mice became moribund. Tumors and
spleens from control and tumor-bearing mice were weighed on a microbalance.
Clonogenic assay for metastatic tumor cells: 4T1 tumor cells are 6-thioguanine (6TG)-resistant, 4T1 metastatic cells can be detected and quantified in tissues by plating
dissociated cells in medium supplemented with 6-thioguanine, and counting the number
of 6-TG-resistant clonogenic tumor cells. This method allows for quantitative
monitoring of spontaneous metastasis at multiple distant sites. Mice were challenged
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s.c. in the abdominal mammary gland with 7x103 4T1 tumor cells and sacrificed at
indicated time. Lungs, brains and livers were harvested from each experimental group.
Liver samples were finely minced and digested in 5 ml of enzyme cocktail containing
1xPBS, 0.01% BSA and 1 mg/ml hyaluronidase, and 1mg/ml collagenase type I for 20
min at 37 °C on platform rocker. Lung samples were finely minced and digested in 5 ml
of enzyme cocktail containing 1xPBS, 1mg/ml collagenase type IV and 6 units/ml for
75 min at 4 °C on a rotating wheel. Brain samples were finely minced and digested for
2h at 37 °C on a platform rocker with 5 ml of the same enxyme cocktail used for lung
samples. After incubation, samples were filtered through 70-µm nylon cell-strainers
and washed twice or three times with 1xPBS. The resulting cells were plated with a
series of dilutions on 10-cm tissue-culture dishes in DMEM containing 60 µM 6thioguanine. Resistant metastatic tumor cells formed foci after 10 to14 days, at which
time they were fixed with methanol and stained with 0.03% methylene blue. Clonogenic
metastases were calculated on a per-organ basis.
Detection of protein Nitration: Cells were seeded in 10-cm plates in duplicates. Half
of the plates were incubated under hypoxic conditions (1% of O2), while another half
(control) were incubated under normoxic conditions for 24 hrs. Cells were washed 3
times with ice-cold 1xPBS, scraped in 1 ml of the ice-cold Lysis Buffer (50mM TrisHCl (pH 7.4); 150mM NaCl; 1% Triton x-100; 0.1% SDS; 2.5mM EDTA; Halt
Cocktail of protease inhibitors (Thermo Scientific), then incubated on ice for 20 min.
Cell lysates were collected by centrifugation at 12,000 rpm for 20 min. 10 ul of Anti83

Nitrotyrosine Ab (Millipore) and 15 µl of Protein A Agarose (Sigma) were added to
each sample for immunoprecipitation. Samples were rotated overnight at 4 °C. After
incubation, Protein A Agarose beads were pelleted by the centrifugation at 2,500 rpm
for 1 min and pellets were washed 2x times with ice-cold Washing Buffer (lysis buffer
with no protease inhibitors), and 1x time with ice-cold 1xPBS, beads were resuspended
in 1x Laemmli Buffer and boiled for 5 min. After boiling, the beads were spun down.
proteins were resolved in SDS-PAGE and western blotted with Anti-Nitrotyrosine Ab
(Millipore).
Statistical analysis: The tumor volume and metastatic colonies were analyzed by
analysis of variance (ANOVA).

For other data, differences between the two groups

were analyzed with the Student's t-test.

Results of tumor growth are presented as the

means ± standard errors (SE) of tumor area in each group. In vitro assays were repeated
in three times. A p value less than 0.05 was considered as statistically significant.

3. 4 Results
Expression of MLS-stat3 and its variants
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Stat3 expression is required for the in vivo growth of 4T1 cells as well as their invasion
in vitro (32). Mitichondrial Stat3 regulates the ability of H-ras to transform MEFs, and
this process requires serine ser 727 (21). Therefore, we examined whether
mitochondrial-targeted Stat3 influenced the ability of 4T1 cells to grow and metastasize.
To determine whether the actions of MLS Stat3 are mediated through serine 727 and/or
Y705, or the DNA-binding domain (DBD) or SH2 domain, we generated stable 4T1 cell
lines expressing either MLS Stat3Y705F, MLS Stat3 S727A, , MLS Stat3
Y705F/S727A, MLS Stat3 Y705F/S727D, MLS Stat3 DBD or MLS Stat3 SH2. Stat3
and its variants were fused with a mitochondrial targeting sequence (MLS) derived from
cytochrome c oxidase subunit VIII which is a component of electron transport chain (44)
(Fig.3.1). This sequence exclusively targets the protein of interest to the inner
mitochondrial membrane. 4T1 cells were infected with MSCV retrovirus which express
variants of MLS Stat3. The vector (MSCV) also contains an IRES that drives the
expression of GFP. GFP positive cells were selected by FACS sorting. Subcellular
fractionation of MLS Stat3-expressing cells demonstrated that Stat3 was present only
the mitochondria and not in the cytoplasm (Fig.3.2).
MLS Stat3 is not involved in Stat3-dependent transcription
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Fig.3.1 Domain structure of MLS Stat3

Three types of 4T1 stable cell lines were

generated. (1) 4T1 cells expressing MSCV empty vector; (2) 4T1 cells expressing MLS
Stat3; (3) 4T1 cells expressing MLS mutated Stat3. There are 4 types of mutated Stat3:
(1) transcriptionally inactive Stat3: (i) Y705F; (ii) DBD (E434A/E435A); (iii) SH2
(R609Q); (2) serine 727 can not be phosphorylated: S727A; (3) Serine 727 is a
phosphomimetic:

S727D;

(4)

Combinations

of

Y705F/S727A/SH2, Y705F/S727D, Y705F/S727D/SH2.
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mutations:

Y705F/S727A,

Fig. 3.2 MLS Stat3 and its variants were expressed only in mitochondria. Total cell
lysates ( TCE ), cytoplasmic lysates, and mitochondrial lysates ( mito ) were isolated,
separated by SDS-PAGE and the immunoblotted for the expression of Stat3, α-tubulin
( a cytosolic protein marker ), and the 30 KDa subunit of complex II ( a mitochondrial
protein marker ). MLS Stat3 and its various mutation forms are the upper bands and
endogenous Stat3 migrates as the lower band.

To examine whether the expression of MLS Stat3 and its variants alters Stat3-dependent
transcriptional activity, we assayed the expression of C/EBP δ RNA which is a well
87

characterized immediate early gene whose transcription is activated by Stat3. 4T1 cells
expressing various forms of MLS Stat3 were serum-starved for 3 hrs, and then
incubated with or without mouse oncostatin M (OSM) for 4 hrs. RNA was isolated and
C/EBP δ RNA expression was analyzed using quantitative RT-PCR (Fig.3.3). OSMstimulated expression of C/EBP δ RNA was increased approximately 5-fold in all cell
lines. This observation is consistent with the well-described requirement for Stat3
tyrosine phosphorylation to induce the expression of nuclear-encoded genes, and also
indicates that expression of MLS Stat3 does not alter the activation of nuclear-encoded
Stat3-dependent genes.
MLS Stat3 Y705F/S727D showed better cell growth than MLS Stat3 S727A and
Y705F/S727A mutant in low glucose.
Activated Stat3 promotes cell survival and proliferation in cancer , whereas inhibition of
Stat3 suppresses cancer cell growth (32). To examine the effect of mitochondriallocalized Stat3 (MLS Stat3) on cell growth, we assayed 4T1 cell growth in cells
expressing various forms of MLS Stat3. No significant difference in cell growth rates
was observed among these variants under normal growth conditions (normal growth
medium supplemented with 10% FBS, 4.5 g/L glucose) by MTT assay (Fig.3.4(A)) or
by cell counts (Fig.3.4(B)), suggesting that the intrinsic growth rates of the cells is not
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Fig.3.3 MLS Stat3 and its variant do not alter Stat3-dependent transcription. Total
RNAs were isolated with Trizol reagent (Invitrogen) from untreated 4T1 cells and 4T1
cells expressing MLS Stat3 and variants. Cells were serum-starved for 3 h and then
treated with murine oncostatin (500 ng/ml) for 4 h. 2 µg of total mRNA from the
respective samples were used to generate cDNA. The expression of C/EBPδ RNA was
determined by quantitative RT-PCR analysis. Samples were normalized to the
expression of β-actin.
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altered by expression of various mutations of MLS Stat3 under normal conditions of
cell culture. We then determined the survival and growth of these variants under
stressful conditions. Cells were grown in DMEM containing low glucose (0.5 g/L of
glucose) for 48 hrs or 72 hrs. Cell numbers were assayed by Coulter counter. As shown
in Fig.3.5,

MLS Stat3 Y705F/S727A and MLS Stat3 S727A mutant cells grew

significantly slower, whereas MLS Stat3 Y705F/S727D mutant cells showed a
significant growth advantage compared with the other MLS Stat3 variants. No apparent
growth difference was observed among other mutant cells. Our data supports the
findings that serine 727 phosphorylation in Stat3 promotes macrophage survival in the
absence of detectable Y705 phosphorylation. This was further corroborated by findings
demonstrating that phosphorylation at Serine 727 of Stat3, but not Y705, was critical in
enhancing survival effects in neuronal stem cells (2) and macrophage survival (33). It is
also consistent with the findings that serine phosphorylation of MLS Stat3 is essential
for mitochondrial respiration (44).
MLS Stat3 YFSA and S727A mutants display reduced anchorage-independent
growth in vitro
To examine whether MLS Stat3 regulates the transforming activity of 4T1 cells, we
measured the ability of variants to form colonies in soft agar. MLS Stat3 Y705F/S727A
and S727A mutants formed fewer colonies (Fig.3.6), whereas Y705F/S727D formed 3fold more colonies than S727A (p < 0.05; Fig. 3.6). These observations suggest that
serine 727 phosphorylation of MLS Stat3 contributes to transformation by 4T1 cells.
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Fig.3.4 MLS Stat3 does not regulate cell growth under normal conditions of cell
culture (A) MTT proliferation assay. 4000 cells were seeded per well in 96-well plates
in triplicate. (B) Growth rates in high glucose (4.5 g/L, i.e, 24.8 mM ) media. 35,000
cells were seeded in per well in 12-well plates.
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Fig.3.5 MLS Stat3 S727A and Y705F/S727A mutants have reduced cell growth in
low-glucose media Growth rates in 35000 cells were seeded in per well in 12-well
plates and grew in low glucose (0.5 g/L, i.e, 2.75 mM ). The cell numbers were counted
at indicated time.
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Fig.3.6 MLS Stat3 Y705F/S727A and S727A show reduced anchorage-independent
growth Cells (1 × 103) were seeded in triplicate in 0.35% low-melting agar in 60-mm
dishes, prepared in standard growth media. Cells were cultured in a humidified
incubator at 37 °C and 5% CO2 for 10-12 days. Colonies greater than 0.2 mm2 were
scored. Two independent experiments were performed in triplicates.
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Serine 727 to alanine mutation of MLS Stat3 impairs cell invasion
To determine whether the expression of MLS Stat3 impacts cell invasion, 4T1 and MLS
Stat3 variants were seeded in Matrigel gel inserts and incubated at 37 °C for 22 hrs.
After incubation, cells were stained and counted. The Y705F/S727A mutant of MLS
Stat3 had the least number of migrating cells than any other cell lines, whereas the
Y705F/S727D mutant of MLS Stat3 showed the highest number of migrating cells
(Fig.3.7), suggesting that serine phosphorylation of MLS Stat3 is important for cell
invasion.
A serine 727 to alanine mutation of MLS Stat3 impairs tumorigenesis
Since mitochondrial Stat3 mediates the ability of H-Ras to transform MEFs (21), we
determined the effect of MLS Stat3 on tumorigenesis of 4T1 cells in vivo. We injected
4T1 cells expressing different MLS Stat3s into the mammary glands of BALB/c female
mice. The serine 727 to alanine mutant of MLS Stat3-expressing cells significantly
slows tumor growth. In contrast, the serine 727 to aspartic acid mutant promotes tumor
growth (Fig.3.8). These results are consistent with our observations that serine
phosphorylation is required for Stat3 function in mitochondria (44) and support the
findings that phosphominmetic serine of Stat3 promotes prostate tumorigenesis (40).
To determine the effect of MLS Stat3 expression on metastasis, clonogenesis assay
were performed in livers and lungs. The serine to alanine mutant of MLS Stat3 has
significantly reduced metastasis in lungs and livers than other cell lines (Fig.3.9). The
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Fig.3.6 Serine 727 to alanine mutation of MLS Stat3 impairs invasion Cells were
seeded in inserts containing serum-free medium. Cells were incubated at 37°C for 22
hours. After incubation, the non-invading cells are removed from the upper surface of
the membrane by gentle “scrubbing”. The cells on the lower surface of the membrane
were stained using DIFF Stain kit and migration was determined by counting cells. (A)
Images of invading cells. (B) The numbers of invading cells. Experiments were done in
triplicate, and at least eight fields were counted in each experiment.
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Fig.3.8 MLS Stat3 Y705FS727A mutant displays decreased tumor growth, whereas
MLS Stat3 Y705FS727D mutant promotes tumor growth. BALB/c female mice
were inoculated with 4T1 cells. Tumors were allowed to grow for 27 days after
inoculation.
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MLS Stat3 Y705F/S727D mutant shows only slightly increase in metastatic disease in
lungs (Fig.3.9(B)). Metastatic colony data of S727D mutant is not consistent with the in
vitro data from the matrigel invasion assay, but the trend in which S727D increases the
metastasis is seen. Although the invasion assay may reflect the ability of metastatic
growth to some extent, successful metastatic growth in vivo depends on several
parameters including invasion and colonization at sites distant from the primary tumors.
MLS Stat3 protects tumor cells from hypoxia
Elevated ROS is observed in ventricles from Stat3-null hearts (25). Complex I of
mitochondrial electron transport chain is a major source of ROS production. Our
previous results show that mitochondrial Stat3 regulates complex I activity of and serine
727 in Stat3 is required for Stat3 function in mitochondria (44). Stat3 has been shown
to interact with complex I of electron transport chain in the mitochondria (44) and also
interacts with Grim19 (45), a subunit of complex I. Therefore, we hypothesized that
MLS Stat3 mediates ROS production. Superoxide reacts with NO to produce
peroxynitrate(ONOO-), which then nitrates tyrosine residues in proteins. Therefore,
nitrated protein levels reflect ROS concentration. 4T1 cells expressing MLS Stat3
variants were cultured under normoxic or hypoxic conditions for 24 hrs. Cell extracts
were prepared and immunoprecipitated with anti-Nitrotyrosine antibody. Immunoblots
were probed with the same antibody. Cells expressing the MLS Stat3 Y705F/S727A
mutant show significantly elevated levels of nitrated proteins than other cell lines.
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Fig.3.9 MLS Stat3 Y705FS727A mutant displays decreased metastatic growth.
BALB/c female mice were inoculated with 4T1 cells. Tumors were allowed to grow for
27 days after inoculation. (A) The number of colonies in livers. p value: vs S727A,
Y705F/S727A: < 0.001; vs S727D: < 0.01. (B) The number of colonies in lungs. p
value: vs S727A, Y705F/S727A: < 0.001; vs S727D: > 0.05.
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Fig.3.10 MLS Stat3 protects tumor cells from hypoxia induced tyrosine
nitrosylation

Cells were seeded and incubated in 1% O2 for 24 h. After incubation,

cell lysates were immunoprecipitated with anti-nitrotyrosine antibody and protein A
agarose. Immunoprecipitates were separated in SDS-PAGE and blots were probed with
anti-Nitrotyrosine antibody. The levels of tyrosine nitrated proteins were quantitated by
densitometry. The bar represents the ratio of the level of tyrosine nitrated proteins under
hypoxia to under normoxia. * represents p < 0.05.
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3.5 Discussion
Stat3 is well-known to mediate cell growth, survival, differentiation and immune
functions. Constitutively activated Stat3 has been seen in many human cancers.
Pharmacological or dominant-negative inhibition of Stat3 activity blocks the
proliferation and survival of breast cancer cells in vitro (7, 18, 31). Clinical studies
demonstrated that increased levels of Stat3 phosphorylation in patients with stage II
breast cancer correlated with an incomplete response to neo-adjuvant chemotherapy (14)
and increased metastasis to regional lymph nodes (26). We used the 4T1 mouse breast
cancer model to demonstrate that mitochondrial-localized Stat3 mediates the
development and metastasis of breast cancer. MLS Stat3 protects tumor cells from
hypoxia. Our data suggests that there is correlation between hypoxia, ROS production
and the effect of MLS Stat3 variants on tumor growth.
In this study, Stat3 and its variants were targeted into mitochondria in 4T1 mouse breast
cancer cells by using a mitochondrial-targeting sequence. We have shown that RNA
levels of C/EBP δ induced by OSM are similar among MLS Stat3 and its variants,
indicating that MLS Stat3 does not influence Stat3-dependent transcriptional activity.
These cells display similar growth rates under standard conditions of cell culture. Under
glucose starvation, MLS Stat3 Y705F/S727A and MLS Stat3 S727A mutants grew
slower than MLS Stat3 and other mutants, whereas MLS Stat3 Y705F/S727D mutant
grew significantly faster than all other MLS Stat3 mutants. Data from MLS Stat3
Y705F/S727D supports the study that Stat3 Y705F/S727E enhances prostate cancer cell
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growth. Data from our studies using Y705F/S727A and S727A is consistent with the
findings that serine phosphorylation of Stat3 appears essential in vivo for postnatal
survival and growth because a knock-in mouse expressing Stat3 with an alanine to
serine replacement at position 727 is not viable (41). Another report shows that S727
phosphorylation of Stat3 is required for macrophage survival in the absence of
detectable Y705 phosphorylation (33). This was further supported by findings
demonstrating that phosphorylation at S727, but not Y705, was critical in enhancing
survival effects in neuronal stem cells (2).
Data from our study is not consistent with one study where over-expression of Stat3
Y705F/S727A in prosate cancer cells didn’t affect growth rate of cells in low serum
medium (0.5% FBS). There are several explanations for this discrepancy. 1) Stat3
Y705F/S727A needs to be targeted to the mitochondria to achieve high enough
concentrations to affect cell growth; 2) The effects of Stat3 Y705F/S727A are different
in different tumors.
We demonstrate that expression of MLS Stat3Y705F/S727A in 4T1 cells inhibits their
ability to grow in soft agar, indicating that serine 727 phosphorylation is required for
efficient tumor growth and transformation. Our observations support the finding that
serine 727 phosphorylation in mitochondrial-localized Stat3 is required for Rasinduced transformation (21). It is also consistent with the finding that overexpressed
Stat3 S727A exerts a dominant–negative effect on v-Src-mediated transformation (5).
Expression of MLS Stat3 Y705F/S727A impairs tumorigenesis and metastasis. This
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observation is consistent with the finding that reconstitution of mitochondrial Stat3
S727A in Stat3-/- MEFs can not restore Ras-induced tumorgenesis. The expression of
MLS Stat3 Y705F/S727D enhances tumor growth, but not metastasis. This observation
is consistent with the finding that a phosphomimetic of serine 727 of Stat3 accelerates
tumorigenesis of human prostate cancer cells in the absence the protein being tyrosine
phosphorylated. The effect of MLS Stat3 Y705F/S727D on metastasis in vivo is not
consistent with its invasion ability in vitro. This maybe due to the fact that tumor
invasion is only one of several steps in metastasis. Following tumor cell extravasation,
several events are needed to permit cells to establish metastatic tumors.
There is very limited information about the mechanism by which mitochondrial Stat3
mediates cellular transformation. A recent study reports that mitochondrial Stat3 may
mediate Ras-dependent cellular transformation by augmenting electron transport chain
activity, particularly that of complexes II and V. Changes in ETC activity could be
accompanied by a metabolic shift. Stat3-null hearts have elevated ROS. MLS Stat3
regulates complex I activity of electron transport chain of mitochondria. Complex I is a
major source where reactive oxygen species. These reports indicate that there is a close
relationship between Stat3 expression and intracellular ROS. Therefore we examined
whether MLS Stat3 alters ROS production. We found that MLS Stat3 Y705F/S727A
and S727A mutants have higher levels of protein tyrosine nitration than other MLS
Stat3 variants subjected to hypoxia, whereas MLS Stat3 Y705F/S727D has the lowest
level of protein tyrosine nitration. This result may suggest that MLS Stat3 mediates
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breast cancer development by protecting tumor cells from hypoxia. Tyrosine-nitrated
proteins have been viewed as dead end products that are destined for protein
degradation. For example, nitration of mitochondrial manganese superoxide dismutase
(MnSOD) may lower its mitochondrial antioxidant potential and contribute to
apoptosis (36). This might be a reason why the serine to alanine mutation of MLS Stat3
shows decreased tumor cell growth rate and decreased metatstasis.
The mechanism by which MLS Stat3 mediates ROS production is unclear. MLS Stat3
might directly regulate ROS production through mediating complex I activity. Another
possibility is that MLS Stat3 mediates the activity of the enzyme which mediates ROS
production. In future experiments, we will investigate how mitochondrial Stat3
regulates hypoxia. Regulation of hypoxia through mitochondrial Stat3 activity could
provide an attractive target for therapeutic approaches to breast cancer.
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Chapter IV Discussion
Members of Jak/Stat signaling pathway are pivotal in mediating cell proliferation,
differentiation, survival, apoptosis and immune responses. Aberrant activation of
Jak/Stats can lead to neoplastic transformation and promotes abnormal cell proliferation
in various malignancies (17, 31, 33, 34, 40, 134). Although the importance of Tyk2 in
host defense is well understood, there is very limited information concerning the role of
Tyk2 in the pathogenesis of malignancies. One study shows that the expression of Tyk2
and its signaling enhances invasion of prostate cancer cells in vitro without affecting
their rate of growth (51). In contrast, Tyk2-/- mice have been shown to develop Abelsoninduced B leukemia and Tel-Jak2-induced T leukemia with higher incidence and
shortened latency compared to wild type mice (111). To explore the role of Tyk2 in the
pathogenesis of breast cancer, we used the 4T1 mouse mammary breast cancer model.
4T1 cells were derived from mammary carcinomas which spontaneously grow in
immunocompetent Balb/C mice and can spontaneously metastasize from the primary
tumor to lung, liver, brain and lymph node. This model allows us to study immune
responses in immunocompetent BalB/c mice. 4T1 cells are resistant to 6-thioguanine,
allowing precise measurement of metastatic disease. Here, we show that the deletion of
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Tyk2 results in increased primary tumor growth and metastastic growth as well as
splenomegaly. Tyk2-/- mice also produce less IFNγ than WT mice. We have shown that
CD4+ T cells are not involved in antitumor activity in 4T1-tumor bearing mice.
Surprisingly, neither Tyk2-/- NK cells alone nor CD8+ T cells alone contribute the
enhanced tumor growth in Tyk2-/- mice. Our finding contrasts with the reported role of
Tyk2-/- NK cells in the pathogenesis of Abelson-induced B leukemia and Tel-Jak2induced T leukemia (111). This discrepancy maybe due to tissue specific actions of
NK/NKT cells in tumor surveillance.
Stat3 is a member of transcription factors that primarily resides in the cytoplasm.
Overexpression of Stat3 promotes cell growth and transformation. Stat3 is critical for
mammary development. Many human tumors displayed elevated levels of tyrosine
phosphorylated Stat3 . Approximately 75% of primary human breast cancer show
elevated levels of tyrosine phosphorylated Stat3 (24, 34, 122).

Clinical studies

demonstrate that increased levels of Stat3 phosphorylation in patients with stage II
breast cancer correlated with an incomplete response to neo-adjuvant chemotherapy
(42). Although constitutively tyrosine phosphorylation of Stat3 has been implicated in
the pathogenesis of many cancers, there is accumulating evidence that serine 727
phosphorylation of Stat3 can contribute to or is sufficient for growth and or
transformation of some malignancies (10, 31, 94, 120). However, it is very little known
about the role of Stat3 serine 727 in tumor growth and invasion of these tumor cells.
Recent publications indicate that a small portion of Stat3 localizes in mitochondria,
modulates the activity of complexes I, II, and V of the ETC (126) and regulates the
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ability of Ras to transform MEFs (39). These processes require serine 727. We therefore
examined whether mitochondria-targeted Stat3 influenced the ability of 4T1 mouse
breast cancer cells to grow and metastasize in vivo. We show here that tumor volumes
were all significantly decreased in 4T1 cells expressing MLS Stat3Y705F/S727A or
MLS Stat3 S727A compared with cells expressing MSCV, MLS Stat3 or MLS
Stat3Y705F/S727D. There was a significant decrease in the numbers of metastatic
colonies in cells expressing MLS Stat3Y705F/S727A compared to cells expressing
MLS Stat3. These findings suggest that expression of Stat3 that is targeted to the
mitochondria can influence the growth and metastatic potential of 4T1 breast cancer
cells in vivo. We have shown that the expression of mitochondrial-targeted Stat3 does
not alter cell growth rates in vitro under normal conditions, but expression of Stat3
S727A results in a significant decrease in cell growth under glucose starvation and
affects growth of cells in soft agar and their ability to invade in vitro. Furthermore, the
expression of mitochondrial-targeted Stat3 does not mediate the transcription activity of
Stat3. Since ROS production is associated with Stat3 expression and activation (47), we
examined whether mitochondrial-targeted Stat3 affects ROS production. Interestingly,
under conditions of hypoxia, Stat3 S727A displays elevated levels of protein nitration –
a marker of ROS production. In contrast, MLS Stat3 S727D has decreased levels of
protein nitration compared with MLS Stat3, suggesting that mitochondrial-targeted
Stat3 protects 4T1 tumor cells from hypoxia and ROS accumulation. We hypothesized
that mitochondrial-targeted Stat3 affects the activity of complex I which is a major
source of ROS production.
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Thus, our present study provides the first evidence that both Tyk2 and mitochondrialtargeted Stat3 in mediating the pathogenesis of breast cancer by different mechanisms.
Future studies need to focus on investigating whether any alterations in the expression
and/or activity of these proteins are associated with other malignancies.
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